Development and application of immune cell activators

Abstract

The present invention provides the development and application of anti-OX40 antibodies and immune cell activators, and the anti-OX40 antibodies or fragments thereof of the present invention retain relatively strong binding to human OX40 or rhesus monkey OX40.

Description

[Technical Field]

[0001] The present invention relates to the field of biological immunotechnology, and in particular to novel antibodies and antibody fragments that specifically bind to OX40. [Background technology]

[0002] There are two types of immune system test points: inhibitory, such as PD-1, and activating, such as OX40. Full activation of T cells in the immune system requires two signaling stages. The first signal is generated by the T cell antigen receptor (TCR) that recognizes the antigen and transmits an activation signal intracellularly via the CD3 molecule. The second signal, called a costimulatory signal, is generated by the interaction of costimulatory molecules on the surface of antigen-presenting cells or target cells with costimulatory molecule receptors on the surface of activated T cells. Costimulatory signals promote the proliferation of antigen-specific T cells and their differentiation into effector T cells. (Lindsay K et al., Immunity 2016, 44(5):1005-1019)

[0003] OX40, also known as TNFRSF4, ACT35, or CD134, is a type I transmembrane glycoprotein that belongs to the tumor necrosis factor receptor superfamily (TNFRSF). OX40 is not expressed on resting T cells, but is expressed on activated CD4+ T cells, CD8+ T cells, NK cells, and NKT cells (Paterson DJ et al. Mol. Immunol. 1987;24:1281-1290). T cells can express high levels of OX40 within 1–3 days after antigen activation. OX40 signaling further enhances T cell activation signals, enhancing immune system responses (Gramaglia I et al. J. Immunol. 2000;165:3043-3050).

[0004] OX40L, also known as TNFSF4, TXGP1, gp34, and CD252, is a type II transmembrane glycoprotein and natural ligand for OX40. It exists in a trimeric form on activated antigen-presenting cells (APCs), such as DCs and B cells, and is expressed through the mediation of CD40, toll-like receptors (TLRs), and inflammatory factors. OX40L is also widely present in non-hematopoietic cells, such as smooth muscle and vascular endothelial cells (Murata K et al. J. Immunol. 2002;169:4628-4636).

[0005] The OX40 signaling pathway activated by OX40L is linked to multiple signaling pathways in T cells. After trimeric OX40L, formed by intramolecular disulfide bonds, binds to OX40 on the T cell membrane (Compaan DM et al. Structure. 2006;14:1321-30), it can initially activate the OX40 signaling pathway. Further or fully activating the OX40 signaling requires further oligomerization of the receptor, forming hexamers or larger (H Wajant. Cell Death and Differentiation (2015) 22,1727-1741). After activation, OX40 recruits TNF receptor-associated factors (TRAFs) 2 and 5 via its intracellular domain, activating the NFκB signaling pathway and exerting anti-apoptotic effects, suppressing cell apoptosis (Song J et al. J. Immunol. 2008;180:7240-8).

[0006] The OX40 signaling pathway specifically supports the TCR signaling pathway in T cells, primarily the PKB / PI3K and calcium ion-related NFAT signaling pathways. The former promotes the survival and cell cycle progression of activated T cells (Song J et al. NatImmunol. 2004;5:150-8). The latter primarily promotes the proliferation of activated T cells and the secretion of relevant cytokines (So T et al. Proc Natl Acad Sci USA. 2006;103:3740-5).

[0007] Some researchers have found that OX40 can be highly expressed on tumor-infiltrating CD4+ Treg cells (regulatory T cells). Treg cells can suppress effector T cells (Teff). Currently, there is no unified and clear view on the regulatory role of the OX40 signaling pathway on Treg cell function. Several studies have suggested that the OX40 signaling pathway can suppress the immunosuppressive function of Treg cells (Piconese S et al. J. Exp. Med. 2008;205:825-39; Voo KS et al. J. Immunol. 2013;191:3641-50). We have found that OX40 is required for Treg cells to fully exert their immunosuppressive function (Piconese S et al. Eur. J. Immunol. 2010;40:2902-13; Griseri T et al. J. Exp. Med. 2010;207:699-709). The effects of the OX40 intracellular signaling pathway on Treg cell proliferation and apoptosis vary depending on the microenvironment in which the cells reside. We also found that OX40 activation can potently promote Treg cell proliferation in the absence of IFN-γ and IL-4 or in the presence of FoxP3 expression (Ruby CE et al. J. Immunol. 2009;183:4853-7). In other microenvironments, OX40 activation had no effect on Treg cell proliferation (Vu MD et al. Blood. 2007;110:2501-10).

[0008] Currently, anti-OX40 antibodies are thought to achieve their immune system T cell activation and tumor suppression effects primarily through the following three cellular physiological mechanisms: 1) direct activation of CD4+ and CD8+ effector T cells, promoting their proliferation, survival, and secretion of related inflammatory factors; 2) suppression of Treg signaling and activity, thereby weakening their suppressive effect on the immune system; and 3) depletion of Treg cells, such as by ADCC or ADCP, thereby reducing their suppressive effect on effector T cells (J. Willoughby et al., Molecular Immunology 83, 2017, 13-22). The concept of using anti-OX40 antibodies or the OX40 signaling pathway to treat tumors has already received strong validation from numerous mouse tumor models. Previous studies have strongly suggested that OX40 is a highly potent activating target in tumor immunotherapy, providing a new avenue for tumor immunotherapy. Summary of the Invention

[0009] The present invention provides a novel antibody or fragment thereof that can specifically recognize and bind to OX40 (particularly human OX40 (hOX40)). The antibody or fragment thereof can bind to hOX40 with higher affinity, and can activate T cells more effectively without competing with OX40 ligand (OX40L), generating a stronger immune response and enhancing antitumor activity.

[0010] The present invention discloses an antibody or an antigen-binding fragment thereof, wherein the antibody or fragment thereof specifically binds to OX40, and the antibody or fragment thereof is (a) a VH CDR1 as shown in SEQ ID NO: 1, 4, 10, 16, 104 or 22; (b) a VH CDR2 as set forth in SEQ ID NO: 2, 5, 7, 8, 11, 13, 14, 17, 20, 23 or 26; (c) a VH CDR3 as set forth in SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24 or 27; (d) a VL CDR1 as set forth in SEQ ID NO: 28, 31, 37, 40, 43, 46, 49, 52, 55, 58 or 61; (e) a VL CDR2 as set forth in SEQ ID NO: 19, 25, 29, 32, 35, 38, 44, 47, 50, 56, 59 or 62; (f) comprises one or more amino acid sequences of VL CDR3 shown in SEQ ID NO: 30, 33, 34, 36, 39, 41, 42, 45, 48, 51, 53, 54, 57, 60 or 63.

[0011] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO: 1, 4, 10, 16, 104, or 22. In some embodiments, the antibody or fragment thereof comprises a VH CDR2 set forth in SEQ ID NO: 2, 5, 7, 8, 11, 13, 14, 17, 20, 23, or 26. In some embodiments, the antibody or fragment thereof comprises a VH CDR3 set forth in SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, or 27. In some embodiments, the antibody or fragment thereof comprises a VL CDR1 set forth in SEQ ID NO: 28, 31, 37, 40, 43, 46, 49, 52, 55, 58, or 61. In some embodiments, the antibody or fragment thereof comprises a VL CDR2 set forth in SEQ ID NO: 19, 25, 29, 32, 35, 38, 44, 47, 50, 56, 59, or 62. In some embodiments, the antibody or fragment thereof comprises a VL CDR3 set forth in SEQ ID NO: 30, 33, 34, 36, 39, 41, 42, 45, 48, 51, 53, 54, 57, 60, or 63.

[0012] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO: 10. In some embodiments, the antibody or fragment thereof comprises a VH CDR2 set forth in SEQ ID NO: 7, 11, 13, or 26. In some embodiments, the antibody or fragment thereof comprises a VH CDR3 set forth in SEQ ID NO: 12 or 27. In some embodiments, the antibody or fragment thereof comprises a VL CDR1 set forth in SEQ ID NO: 37, 43, or 61. In some embodiments, the antibody or fragment thereof comprises a VL CDR2 set forth in SEQ ID NO: 19, 25, 38, 44, or 62. In some embodiments, the antibody or fragment thereof comprises a VL CDR3 set forth in SEQ ID NO: 34, 39, 41, 45, 53, or 63.

[0013] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:1, 4, 10, 16, 104 or 22, a VH CDR2 set forth in SEQ ID NO:2, 5, 7, 8, 11, 13, 14, 17, 20, 23 or 26, and a VH CDR3 set forth in SEQ ID NO:3, 6, 9, 12, 15, 18, 21, 24 or 27. In some embodiments, the antibody or fragment thereof comprises a VL CDR1 set forth in SEQ ID NO:28, 31, 37, 40, 43, 46, 49, 52, 55, 58 or 61, a VL CDR2 set forth in SEQ ID NO:19, 25, 29, 32, 35, 38, 44, 47, 50, 56, 59 or 62, and a VL CDR3 set forth in SEQ ID NO:30, 33, 34, 36, 39, 41, 42, 45, 48, 51, 53, 54, 57, 60 or 63.

[0014] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO: 1, 4, 10, 16, 104 or 22, a VH CDR2 set forth in SEQ ID NO: 2, 5, 7, 8, 11, 13, 14, 17, 20, 23 or 26, a VH CDR3 set forth in SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24 or 27, a VL CDR1 set forth in SEQ ID NO: 28, 31, 37, 40, 43, 46, 49, 52, 55, 58 or 61, a VL CDR2 set forth in SEQ ID NO: 19, 25, 29, 32, 35, 38, 44, 47, 50, 56, 59 or 62, and a VL CDR3 ... and a VL CDR2 set forth in SEQ ID NO: 28, 31, 37, 40, 43, 46, 49, 52, 55, 58 or 61, and a VL Contains a VL CDR3 as shown in NO: 30, 33, 34, 36, 39, 41, 42, 45, 48, 51, 53, 54, 57, 60 or 63.

[0015] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:10, a VH CDR2 set forth in SEQ ID NO:7, 11, 13 or 26, a VH CDR3 set forth in SEQ ID NO:12 or 27, a VL CDR1 set forth in SEQ ID NO:37, 43 or 61, a VL CDR2 set forth in SEQ ID NO:19, 25, 38, 44 or 62, and a VL CDR3 set forth in SEQ ID NO:34, 39, 41, 45, 53 or 63.

[0016] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:1, a VH CDR2 set forth in SEQ ID NO:2, a VH CDR3 set forth in SEQ ID NO:3, a VL CDR1 set forth in SEQ ID NO:28, a VL CDR2 set forth in SEQ ID NO:29, and a VL CDR3 set forth in SEQ ID NO:30.

[0017] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:4, a VH CDR2 set forth in SEQ ID NO:5, a VH CDR3 set forth in SEQ ID NO:6, a VL CDR1 set forth in SEQ ID NO:31, a VL CDR2 set forth in SEQ ID NO:32, and a VL CDR3 set forth in SEQ ID NO:33.

[0018] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:1, a VH CDR2 set forth in SEQ ID NO:8, a VH CDR3 set forth in SEQ ID NO:9, a VL CDR1 set forth in SEQ ID NO:31, a VL CDR2 set forth in SEQ ID NO:35, and a VL CDR3 set forth in SEQ ID NO:36.

[0019] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:10, a VH CDR2 set forth in SEQ ID NO:11, a VH CDR3 set forth in SEQ ID NO:12, a VL CDR1 set forth in SEQ ID NO:37, a VL CDR2 set forth in SEQ ID NO:38, and a VL CDR3 set forth in SEQ ID NO:39.

[0020] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:10, a VH CDR2 set forth in SEQ ID NO:11, a VH CDR3 set forth in SEQ ID NO:12, a VL CDR1 set forth in SEQ ID NO:40, a VL CDR2 set forth in SEQ ID NO:29, and a VL CDR3 set forth in SEQ ID NO:42.

[0021] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:10, a VH CDR2 set forth in SEQ ID NO:11, a VH CDR3 set forth in SEQ ID NO:12, a VL CDR1 set forth in SEQ ID NO:43, a VL CDR2 set forth in SEQ ID NO:44, and a VL CDR3 set forth in SEQ ID NO:39.

[0022] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:10, a VH CDR2 set forth in SEQ ID NO:26, a VH CDR3 set forth in SEQ ID NO:27, a VL CDR1 set forth in SEQ ID NO:61, a VL CDR2 set forth in SEQ ID NO:25, and a VL CDR3 set forth in SEQ ID NO:34.

[0023] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:10, a VH CDR2 set forth in SEQ ID NO:14, a VH CDR3 set forth in SEQ ID NO:15, a VL CDR1 set forth in SEQ ID NO:46, a VL CDR2 set forth in SEQ ID NO:47, and a VL CDR3 set forth in SEQ ID NO:48.

[0024] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:16, a VH CDR2 set forth in SEQ ID NO:17, a VH CDR3 set forth in SEQ ID NO:18, a VL CDR1 set forth in SEQ ID NO:49, a VL CDR2 set forth in SEQ ID NO:50, and a VL CDR3 set forth in SEQ ID NO:51.

[0025] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:16, a VH CDR2 set forth in SEQ ID NO:17, a VH CDR3 set forth in SEQ ID NO:18, a VL CDR1 set forth in SEQ ID NO:52, a VL CDR2 set forth in SEQ ID NO:29, and a VL CDR3 set forth in SEQ ID NO:54.

[0026] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:1, a VH CDR2 set forth in SEQ ID NO:20, a VH CDR3 set forth in SEQ ID NO:21, a VL CDR1 set forth in SEQ ID NO:55, a VL CDR2 set forth in SEQ ID NO:56, and a VL CDR3 set forth in SEQ ID NO:57.

[0027] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:22, a VH CDR2 set forth in SEQ ID NO:23, a VH CDR3 set forth in SEQ ID NO:24, a VL CDR1 set forth in SEQ ID NO:58, a VL CDR2 set forth in SEQ ID NO:59, and a VL CDR3 set forth in SEQ ID NO:60.

[0028] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:10, a VH CDR2 set forth in SEQ ID NO:26, a VH CDR3 set forth in SEQ ID NO:27, a VL CDR1 set forth in SEQ ID NO:61, a VL CDR2 set forth in SEQ ID NO:62, and a VL CDR3 set forth in SEQ ID NO:63.

[0029] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:10, a VH CDR2 set forth in SEQ ID NO:11, a VH CDR3 set forth in SEQ ID NO:27, a VL CDR1 set forth in SEQ ID NO:61, a VL CDR2 set forth in SEQ ID NO:62, and a VL CDR3 set forth in SEQ ID NO:34.

[0030] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:10, a VH CDR2 set forth in SEQ ID NO:26, a VH CDR3 set forth in SEQ ID NO:27, a VL CDR1 set forth in SEQ ID NO:61, a VL CDR2 set forth in SEQ ID NO:44, and a VL CDR3 set forth in SEQ ID NO:39.

[0031] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:10, a VH CDR2 set forth in SEQ ID NO:11, a VH CDR3 set forth in SEQ ID NO:12, a VL CDR1 set forth in SEQ ID NO:61, a VL CDR2 set forth in SEQ ID NO:25, and a VL CDR3 set forth in SEQ ID NO:34.

[0032] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:10, a VH CDR2 set forth in SEQ ID NO:26, a VH CDR3 set forth in SEQ ID NO:27, a VL CDR1 set forth in SEQ ID NO:61, a VL CDR2 set forth in SEQ ID NO:25, and a VL CDR3 set forth in SEQ ID NO:39.

[0033] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:10, a VH CDR2 set forth in SEQ ID NO:26, a VH CDR3 set forth in SEQ ID NO:27, a VL CDR1 set forth in SEQ ID NO:61, a VL CDR2 set forth in SEQ ID NO:44, and a VL CDR3 set forth in SEQ ID NO:34.

[0034] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:10, a VH CDR2 set forth in SEQ ID NO:11, a VH CDR3 set forth in SEQ ID NO:27, a VL CDR1 set forth in SEQ ID NO:61, a VL CDR2 set forth in SEQ ID NO:25, and a VL CDR3 set forth in SEQ ID NO:39.

[0035] In some embodiments, the antibody or fragment thereof comprises a VH CDR1 set forth in SEQ ID NO:10, a VH CDR2 set forth in SEQ ID NO:11, a VH CDR3 set forth in SEQ ID NO:27, a VL CDR1 set forth in SEQ ID NO:61, a VL CDR2 set forth in SEQ ID NO:44, and a VL CDR3 set forth in SEQ ID NO:34.

[0036] In some embodiments, the antibody or fragment thereof comprises a heavy chain variable region, wherein the heavy chain variable region comprises an amino acid sequence set forth in SEQ ID NO:64, 65, 66, 67, 68, 69, 70, 71, or 72, or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:64, 65, 66, 67, 68, 69, 70, 71, or 72.

[0037] In some embodiments, the antibody or fragment thereof comprises a heavy chain variable region, wherein the heavy chain variable region comprises an amino acid sequence set forth in SEQ ID NO:67 or 72, or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:67 or 72.

[0038] In some embodiments, the antibody or fragment thereof further comprises a light chain variable region, wherein the light chain variable region comprises an amino acid sequence set forth in SEQ ID NO:73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, or 84, or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, or 84.

[0039] In some embodiments, the antibody or fragment thereof further comprises a light chain variable region, wherein the light chain variable region comprises an amino acid sequence set forth in SEQ ID NO:76, 78, or 84, or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:76, 78, or 84.

[0040] In some embodiments, the antibody or fragment thereof comprises a heavy chain variable region set forth in SEQ ID NO:72 and a light chain variable region set forth in SEQ ID NO:84. In some embodiments, the antibody or fragment thereof is of one of the following isotypes: IgG, IgM, IgA, IgE, or IgD.

[0041] In some embodiments, the antibody or fragment thereof is an IgG isotype, and in some embodiments, the antibody or fragment thereof is an IgG1, IgG2, IgG3, or IgG4 isotype. Without limitation, the antibody or fragment thereof is a chimeric, humanized, or fully human antibody. In one aspect, the antibody or fragment thereof is a humanized antibody.

[0042] In some embodiments, the antibody or fragment thereof further comprises a heavy chain constant region, a light chain constant region, an Fc region, or a combination thereof.

[0043] In some embodiments, the antibodies described herein are of the IgG isotype, hi some embodiments, the constant region of the antibody is of the human IgG1 isotype and has a heavy chain constant region comprising the amino acid sequence set forth in SEQ ID NO:90 and a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO:91. In some embodiments, the antibody constant region is of a human IgG2 isotype and has a heavy chain constant region comprising the amino acid sequence set forth in SEQ ID NO:92 and a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO:93.

[0044] In some embodiments, the constant region of the antibody is a human IgG4 isotype and has a heavy chain constant region comprising the amino acid sequence set forth in SEQ ID NO:94 and a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO:95.

[0045] In some embodiments, the Fc region is an Fc region of a human antibody. In some embodiments, the amino acid at position 345 (Eu numbering) of the human Fc region heavy chain is R (E345R). In some examples, the amino acid at position 440 (Eu numbering) of the human Fc region heavy chain is Y (S440Y). In some examples, the human Fc region comprises the amino acid sequence set forth in SEQ ID NO:88 or SEQ ID NO:89.

[0046] In some embodiments, the heavy chain constant region comprises the amino acid sequence set forth in SEQ ID NO:88, 89, or 90, and / or the light chain constant region comprises the amino acid sequence set forth in SEQ ID NO:91. In some embodiments, the heavy chain constant region comprises the amino acid sequence set forth in SEQ ID NO:90, and / or the light chain constant region comprises the amino acid sequence set forth in SEQ ID NO:91.

[0047] In some embodiments, the antibody or fragment thereof is a chimeric antibody or fragment thereof, or a humanized antibody or fragment thereof, or a fully humanized antibody or fragment thereof.

[0048] In some embodiments, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:86 or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:86, and the light chain comprises the amino acid sequence set forth in SEQ ID NO:87 or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:87.

[0049] In some embodiments, the antibody comprises a heavy chain set forth in SEQ ID NO:86 and a light chain set forth in SEQ ID NO:87.

[0050] In some embodiments, the antibody or fragment thereof is capable of specifically recognizing and binding to human OX40 or rhesus OX40.

[0051] In some embodiments, the antibody or fragment thereof activates, enhances or induces the activity of OX40.

[0052] In some embodiments, the antibody or fragment thereof is capable of activating T cells.

[0053] In some embodiments, the antibody or antigen-binding fragment thereof promotes further activation of activated T cells, causing them to secrete more inflammatory factors.

[0054] In some embodiments, the antibody or antigen-binding fragment thereof is capable of activating the OX40 intracellular signaling pathway.

[0055] In some embodiments, the affinity value K of the antibody or fragment thereof for OX40 D In some embodiments, the affinity value K of the antibody or fragment thereof for OX40 is ≦5 nM. D In some embodiments, the affinity value K of the antibody or fragment thereof for OX40 is ≦3.5 nM. D In some embodiments, the affinity value K of the antibody or fragment thereof for OX40 is ≦2 nM. D In some embodiments, the affinity value K of the antibody or fragment thereof for OX40 is ≦1 nM. D ≦0.2 nM.

[0056] In some embodiments, the antibody or fragment is a monoclonal antibody or fragment.

[0057] In some embodiments, the antibody or fragment thereof is expressed in CHO cells. In some embodiments, the antibody or fragment thereof is expressed in a genome-edited CHO cell, which expresses an antibody or fragment thereof with low or no fucose content. In some embodiments, the genome-edited CHO cell is a CHO cell in which one or more of the α-1,6-fucosyltransferase gene (fut8 gene), GDP-mannose 4,6-dehydratase (GMD) gene, GDP-4-keto-6-deoxymannose-3,5-epimerase-4-reductase (GMER) gene, and GDP-fucose transporter (GFT) gene (e.g., Slc35c1 gene) have been reduced or knocked out. In some embodiments, the antibody or fragment thereof is expressed in a CHO cell in which the fut8 gene has been knocked out.

[0058] In some embodiments, one, two, or three amino acid residues of the antibody or fragment thereof are fucose-modified.

[0059] In some embodiments, the antibody or fragment thereof has a fucose content of no more than 10%. In some embodiments, the antibody or fragment thereof has a fucose content of no more than 5%. In some embodiments, the antibody or fragment thereof has a fucose content of no more than 1%. In some embodiments, the antibody or fragment thereof has a fucose content of no more than 0.5%. In some embodiments, the antibody or fragment thereof is not conjugated to fucose.

[0060] In some embodiments, the antibody or fragment thereof is an isolated antibody or antigen-binding fragment thereof.

[0061] In some embodiments, the invention further provides a polynucleotide, wherein the polynucleotide encodes the antibody or fragment thereof. In some embodiments, the polynucleotide is an isolated polynucleotide.

[0062] In some embodiments, the polynucleotide comprises one or more of the nucleotide sequences set forth in SEQ ID NOs:96-101. In some embodiments, the polynucleotide comprises the nucleotide sequence set forth in SEQ ID NOs:96, 97, and 98. In some embodiments, the polynucleotide comprises the nucleotide sequence set forth in SEQ ID NOs:99, 100, and 101. In some embodiments, the polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO:102. In some embodiments, the polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO:103. In some embodiments, the polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO:102 and / or the nucleotide sequence set forth in SEQ ID NO:103.

[0063] In some embodiments, the present invention further provides a carrier comprising one or more polynucleotides encoding the antibody or fragment thereof. In some embodiments, the carrier is an isolated carrier. In some embodiments, the carrier is an expression vector comprising a plasmid or a virus.

[0064] In some embodiments, the present invention further provides cells comprising one or more polynucleotides encoding the antibodies or fragments thereof. In some embodiments, the cells are isolated cells. In some embodiments, the cells are CHO cells. In some embodiments, the cells comprise the carrier. In some embodiments, the genome of one or more of the cells is edited, and the CHO cells express an antibody or fragment thereof with low or no fucose content. In some embodiments, the genome-edited CHO cells are CHO cells in which one or more of the Slc35c1 gene, fut8 gene, GDP-mannose 4,6-dehydratase (GMD) gene, GDP-4-keto-6-deoxymannose-3,5-epimerase-4-reductase (GMER) gene, and GDP-fucose transporter (GFT) gene have been reduced or knocked out.

[0065] In some embodiments, the present invention further provides a composition comprising said antibody or fragment thereof, said polynucleotide, or said cell, and a pharmaceutically acceptable carrier.

[0066] In some embodiments, the present invention further provides a method of treating cancer or an infection in a patient in need thereof, comprising administering to said patient an effective amount of said antibody or fragment thereof. In some embodiments, the present invention further provides a use of an antibody or fragment thereof described herein in the treatment of cancer or an infection. In some embodiments, the present invention further provides a use of an antibody or fragment thereof described herein in the preparation of a medicament for treating cancer or an infection.

[0067] In some embodiments, the cancer is a solid tumor.

[0068] In some embodiments, the cancer is selected from non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), multiple myeloma (MM), breast cancer, ovarian cancer, head and neck cancer, bladder cancer, melanoma, colorectal cancer, pancreatic cancer, lung cancer, leiomyoma, leiomyosarcoma, glioma, glioblastoma, etc. Solid cancers include, for example, breast cancer, ovarian cancer, lung cancer, prostate cancer, melanoma, colorectal cancer, head and neck cancer, bladder cancer, esophageal cancer, liver cancer, and kidney cancer.

[0069] In some embodiments, the method further comprises administering to the patient a second cancer therapeutic agent.

[0070] In some embodiments, the infection is a viral infection, a bacterial infection, a fungal infection, or a parasitic infection.

[0071] In some embodiments, the present invention further provides a method of treating cancer or an infection in a patient in need thereof, comprising: (a) treating cells ex vivo with an antibody or fragment thereof described herein; and (b) administering the treated cells to the patient. In some embodiments, the method further comprises isolating the cells from the individual prior to step (a). In some embodiments, the cells are isolated from within the patient. In some embodiments, the cells are isolated from a donor individual different from the patient.

[0072] In some embodiments, the cells are T cells. In some embodiments, the T cells are tumor-infiltrating T lymphocytes, CD4+ T cells, CD8+ T cells, or a combination thereof.

[0073] In some embodiments, the invention further provides methods for detecting OX40 expression in a sample, contacting the sample with an antibody or fragment thereof described herein, causing the antibody or fragment thereof to bind to OX40, and detecting said binding, which reflects the expression level of OX40 in the sample. In some embodiments, the sample comprises tumor cells, tumor tissue, infected tissue, or a blood sample.

[0074] In some embodiments, the present invention further provides a method of treating a disease requiring enhanced immune function in a patient in need thereof, comprising administering to said patient an effective amount of said antibody or fragment thereof.

[0075] The present invention provides antibodies or fragments thereof that bind to human OX40 or rhesus monkey OX40, wherein the anti-OX40 antibodies or fragments thereof of the present invention retain relatively strong binding to human OX40 or rhesus monkey OX40. [Brief explanation of the drawings]

[0076] [Figure 1] Figure 1 shows a flow diagram of the binding of candidate antibodies to Jurkatx cells with highly expressed OX40. The X-axis shows the fluorescence intensity of 50 nM hOX40-FC binding. [Figure 2] Figure 1 shows that antibody-F23-32k does not bind to Jurkat-TIM3, Jurkat-CTLA4, Jurkat-TIGIT, CHO and raji cells. [Figure 3] This shows that the in vitro activating activity of candidate antibodies is detected using an NFκB reporter gene system. [Figure 4] The NFκB reporter gene system was used to detect in vitro activation activity when the candidate antibody was aggregated using protein A. The EC50 values ​​in Figure 4 are in μg / ml. [Figure 5] Detection of PBMCs after SEB activation, showing secretion levels of IL-2 inflammatory factor under stimulation with the antibody of the invention. [Figure 6]Using an NFκB reporter gene system, we demonstrate the in vitro activation activity of the experimental antibody Fc mutants 32k-RY and 32k-R, and the change in that activation activity in the presence of protein A or raji. [Figure 7] 1 shows the inhibitory effect of candidate antibodies on tumor (MC38) growth in vivo. [Figure 8] The binding ability of the affinity-matured antibody to OX40 on the cell surface is shown, and the EC50 values ​​in FIG. 8 are in nM. [Figure 9] Detection of candidate antibody ADCC effectors is shown. The EC50 values ​​in Figure 9 are in μg / ml. [Figure 10] We demonstrate that an NFκB reporter gene system can be used to detect in vitro activating activity of affinity-matured antibodies in the presence of Raji cells. [Figure 11] 1 shows the inhibitory effect of candidate antibodies on tumor (MC38) growth in vivo. [Figure 12] 1 shows the inhibitory effect of affinity-matured antibodies on tumor (MC38) growth in vivo on day 21. [Figure 13] Detection of ADCC effectors of antibodies is shown, where the abscissa represents concentration and the ordinate represents cytotoxicity. [Figure 14] Figure 1 shows the effect of antibodies on IL-2 secretion by activated PBMC. [Figure 15] 1 shows the effect of antibodies on PBMC cytokine release under non-activating conditions. DETAILED DESCRIPTION OF THE INVENTION

[0077] (definition) Unless otherwise defined, scientific and technical terms used herein have the same meaning as commonly understood by those of ordinary skill in the art. Generally, the nomenclature and techniques used in cell culture, molecular biology, and protein purification described herein are those known and commonly used in the art. Standard techniques were used for recombinant DNA, oligonucleotide synthesis, and cell culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques are performed according to manufacturer's instructions or methods commonly used in the art or described herein. The techniques and methods described above are generally used as known in the art and described in several comprehensive and relatively specific publications referenced and described herein. See Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring, NY (1989)).

[0078] As used herein, the term "polypeptide" is intended to encompass both the singular "polypeptide" and the plural "polypeptides," and refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (sometimes called peptide bonds). The term "polypeptide" refers to any single or multiple chains of two or more amino acids, and does not refer to a specific length of the product. Thus, the definition of "polypeptide" includes peptide, dipeptide, tripeptide, oligopeptide, "protein," "amino acid chain," or any other term used to refer to a chain of two or more amino acids, and the term "polypeptide" may be used in place of or interchangeably with any one of the above terms. The term "polypeptide" is also intended to refer to products modified after expression of a polypeptide, including, but not limited to, glycosylation, acetylation, phosphorylation, amidation, derivatization with known protecting / closing groups, proteolytic cleavage, or non-naturally occurring amino acid modifications. A polypeptide may be derived from a natural organism or produced by recombinant technology, but is not necessarily obtained by translation from a designated nucleic acid sequence. It may be produced in any manner, including chemical synthesis.

[0079] "Amino acid" refers to a compound containing two functional groups, an amino group and a carboxyl group, such as an α-amino acid. Two or more amino acids can form a polypeptide through an amide bond (sometimes called a peptide bond). A single amino acid is coded for by a nucleic acid consisting of three nucleotides (so-called codons or base triplets). Each amino acid is coded for by at least one codon. The coding of the same amino acid by different codons is called the "degeneracy of the genetic code." Amino acids include natural amino acids and unnatural amino acids. Naturally occurring amino acids include alanine (three-letter code: Ala, one-letter code: A), arginine (Arg, R), asparagine (Asn, N), aspartic acid (Asp, D), cysteine ​​(Cys, C), glutamine (Gln, Q), glutamic acid (Glu, E), glycine (Gly, G), histidine (His, H), isoleucine (Ile, I), leucine (Leu, L), lysine (Lys, K), methionine (Met, M), phenylalanine (Phe, F), proline (Pro, P), serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), tyrosine (Tyr, Y), and valine (Val, V).

[0080] The term "isolated" as used herein with respect to cells, nucleic acids, polypeptides, antibodies, etc., e.g., "isolated" DNA or RNA, refers to molecules isolated from other components in their natural origin, e.g., naturally occurring DNA or RNA, respectively. As used herein, the term "isolated" also refers to a nucleic acid or polypeptide that is essentially free from cellular material, viral material, or cell culture medium when produced by recombinant DNA technology, or from chemical precursors or other chemicals when chemically synthesized. Note that "isolated nucleic acid" is intended to include nucleic acid fragments that are not present in the natural state. In the present invention, the term "isolated" is also used to refer to cells or polypeptides that are isolated from other cellular proteins or tissues. Isolated polypeptides are intended to include purified and recombinant polypeptides. Isolated polypeptides, antibodies, etc. are typically prepared by at least one purification step. In some embodiments, the purity of an isolated nucleic acid, polypeptide, antibody, etc. is at least 50%, 60%, 70%, 80%, 90%, or 95%.

[0081] As used herein, the term "recombinant" in reference to a polypeptide or polynucleotide refers to a form of a polypeptide or polynucleotide that does not occur in nature and that can be combined to produce a non-naturally occurring polynucleotide or polypeptide.

[0082] "Homology" or "identity" or "similarity" refers to sequence similarity between two polypeptides or two nucleic acid molecules. Homology is determined by comparing alignable positions in each sequence. When a position in the compared sequences is occupied by the same base or amino acid, the molecules are homologous at that position. The degree of homology between sequences is a function of the number of matching or homologous positions shared by the sequences.

[0083] A polynucleotide or polynucleotide region (or polypeptide or polypeptide region) having a certain percentage (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%) of "sequence identity" or "sequence homology" with another sequence means that, upon alignment of the sequences, that percentage of bases (or amino acids) are the same in the two sequences being compared. The alignment and percentage of homology or sequence identity can be determined using software programs known in the art, such as those described in Current Protocols in Molecular Biology, Ausubel et al. eds. (2007). In some embodiments, alignments are performed using default parameters. One alignment program is BLAST, using default parameters. Biologically equivalent polynucleotides refer to polynucleotides that have the percentage of homology specified above and encode polypeptides that have the same or similar biological activity.

[0084] The term "polynucleotide" is used interchangeably with "oligonucleotide" and refers to a polymeric form of nucleotides of any length, whether deoxyribonucleotides, ribonucleotides, or their congeners. Polynucleotides can have any three-dimensional structure and can perform any function, known or unknown. Examples include genes or gene fragments (e.g., probes, primers, ESTs, or SAGE tags), exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, dsRNA, siRNA, miRNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, and isolated DNA and RNA of any sequence. Polynucleotides can also contain modified nucleotides, such as methylated nucleotides and nucleotide analogs. Structural modifications to nucleotides can be made before or after assembly of the polynucleotide. The sequence of nucleotides can be interrupted by non-nucleotide components. Polynucleotides can be further modified after polymerization. The term refers to both double-stranded and single-stranded molecules. Unless otherwise specified or required, any polynucleotide of the present disclosure includes a double-stranded form and each of the two known or predicted complementary single-stranded forms that make up the double-stranded form.

[0085] The term "encoding," when used with reference to a polynucleotide, refers to a polynucleotide that is capable of "encoding" a polypeptide, and that, in its natural state or when manipulated by known methods known to those of skill in the art, can be transcribed and / or translated to produce mRNA for the polypeptide and / or fragments thereof. The antisense strand is the complementary sequence of such a nucleic acid, from which the coding sequence can be derived.

[0086] In the present invention, "antibody" or "antigen-binding fragment" refers to a polypeptide or polypeptide complex that specifically recognizes and binds to an antigen. An antibody may be a complete antibody or any antigen-binding fragment thereof, or a single chain thereof. Therefore, the term "antibody" includes any or all proteins or peptides comprising an immunoglobulin molecule with the biological activity of binding to an antigen. The term "antibody" includes, but is not limited to, the complementarity-determining regions (CDRs) of a heavy or light chain or its ligand-binding portion, including the heavy chain variable region (VH), light chain variable region (VL), heavy chain constant region (CH), light chain constant region (CL), framework region (FR), or any portion thereof. CDRs include the light chain CDR (VL CDR) and the heavy chain CDR (VH CDR). Antibody heavy chain classes include γ, μ, α, δ, and ε, with several subclasses (e.g., γ1 to γ4). The nature of this chain determines the "type" of antibody: IgG, IgM, IgA, IgD, or IgE, respectively. Some may be further classified into immunoglobulin subclasses (isotypes), e.g., IgG1, IgG2, IgG3, and IgG4. Light chain classes include κ and λ. Each heavy chain can bind to a κ or λ light chain. Generally, when immunoglobulins are produced from hybridomas, B cells, or genetically engineered host cells, the light and heavy chains are covalently linked, and the "tails" of the two heavy chains are linked via covalent disulfide bonds or non-covalent bonds. In the heavy chain, the amino acid sequence extends from the N-terminus at the forked ends of the Y configuration to the C-terminus at the base of each chain. The variable region of a κ immunoglobulin light chain is Vκ, and the variable region of a λ immunoglobulin light chain is Vλ. The VL commonly used in the present invention refers to Vκ. Although some of the discussion will refer to the IgG class of immunoglobulin molecules, all immunoglobulin classes are intended to be encompassed within the scope of the presently disclosed claims. For IgG, a typical immunoglobulin molecule comprises two identical light chain polypeptides with a molecular weight of approximately 23,000 daltons and two identical heavy chain polypeptides with a molecular weight of approximately 53,000-70,000 daltons. Both the light and heavy chains may be divided into regions of structural and functional homology. The terms "constant" and "variable" are used according to function. In this regard, it should be understood that the VL and VH determine antigen recognition and specificity.The antigen-binding site on VL and VH can recognize an antigenic determinant and specifically bind to an antigen. The antigen-binding site is defined by three CDRs in VH and VL, respectively (i.e., VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3). The CL and CH (CH1, CH2, or CH3) confer important biological properties, such as secretion, transplacental transport, Fc receptor binding, and complement fixation. According to convention, the numbering of constant regions increases with increasing distance from the antigen-binding site or amino terminus of the antibody. The N-terminal portion is the variable region, the C-terminal portion is the constant region, and the CH3 and CL structural domains are actually the carboxyl termini comprising the heavy and light chains, respectively.

[0087] In the present invention, the heavy chain constant region of an antibody may be derived from different immunoglobulin molecules. For example, the heavy chain constant region of an antibody may comprise a CH1 structural domain derived from an IgG1 molecule and a hinge region derived from an IgG3 molecule. In another example, the heavy chain constant region may comprise a hinge region partially derived from an IgG1 molecule and a hinge region partially derived from an IgG3 molecule. In another example, a portion of the heavy chain may comprise a chimeric hinge region partially derived from an IgG1 molecule and a chimeric hinge region partially derived from an IgG4 molecule. In the present invention, the term "hinge region" includes a portion of the heavy chain structure connecting the CH1 and CH2 structural domains. The hinge region comprises approximately 25 residues and is flexible enough to allow the two N-terminal antigen-binding domains to move independently. As used herein, the term "disulfide bond" includes a covalent bond formed between two sulfur atoms. Cysteine ​​contains a thiol group that can form a disulfide bond with a second thiol group or crosslink. In many naturally occurring IgG molecules, the CH1 and CL regions are linked via a disulfide bond, and the two heavy chains are linked via two disulfide bonds.

[0088] As used herein, the terms "fragment," "antibody fragment," or "antigen-binding fragment" refer to a portion of an antibody, such as F(ab')2, F(ab)2, Fab', Fab, Fv, or scFv. Regardless of its structure, an antibody fragment binds to the same antigen recognized by the intact antibody. The term "antigen-binding fragment" encompasses aptamers, enantiomers, and bivalent antibodies, and further includes any synthetic or genetically engineered protein that forms a complex by binding to a specific antigen and is used as an antibody. "scFv" refers to a fusion protein of immunoglobulin VH and VL. In some embodiments, these regions are linked by a short linker peptide of about 10 to about 25 amino acids. The linker may be glycine-rich to increase flexibility, or serine- or threonine-rich to increase solubility, and may be linked to the N-terminus of VH and the C-terminus of VL, or vice versa. This protein retains the specificity of the original immunoglobulin, despite the removal of the constant regions and the introduction of the linker.

[0089] Antibodies, antigen-binding fragments, variants, or derivatives disclosed in the present invention include, but are not limited to, polyclonal, monoclonal, multispecific, fully humanized, humanized, primatized, or chimeric antibodies, single chain antibodies, epitope-binding fragments.

[0090] As used herein, the term "epitope" includes any protein determinant capable of specific binding to an immunoglobulin or fragment thereof or a T-cell receptor. Epitope determinants typically consist of chemically active surface groups of molecules (e.g., amino acids or sugar side chains) and typically have specific three-dimensional structural characteristics and specific charge characteristics. An antibody can be said to specifically bind to an antigen if the dissociation constant is 1 μM or less (e.g., 100 nM or less, 10 nM or less, or 1 nM or less).

[0091] Where a term has more than one definition as used and / or accepted in the art, the definition of the term as used herein includes all of these meanings unless expressly stated to the contrary.

[0092] Unless otherwise specified, the numbering of residues in each structural domain of an antibody is according to the EU numbering system, also referred to as the EU index, as described, for example, in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed., Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[0093] The antibodies disclosed herein may be derived from any animal, including birds and mammals. Preferably, the antibodies are derived from humans, mice, donkeys, rabbits, goats, guinea pigs, camels, llamas, horses, or chickens. In another example, the variable regions may be derived from Chondrichthyes (e.g., sharks).

[0094] In the present invention, the term "chimeric antibody" is considered to refer to any antibody whose variable regions are obtained or derived from a first species and whose constant regions (which, in the present invention, may be complete, partial, or modified) are derived from a second species. In some examples, the variable regions are of non-human (e.g., murine or primate) origin and the constant regions are of human origin.

[0095] "Specifically binds" or "having specificity for" generally means that an antibody binds to an epitope via its antigen-binding domain, and this binding requires complementarity between the antigen-binding domain and the epitope. According to this definition, if an antibody binds to this epitope via its antigen-binding domain more readily than it would to a random, unrelated epitope, it is said to "specifically bind" to this epitope. The term "specificity" is used in the present invention to qualify the relative affinity of a particular antibody that binds to a particular epitope. The strength or affinity of an immunological binding interaction is determined by the equilibrium dissociation constant (K D ), where a relatively small K Dindicates a relatively strong affinity. The immune binding properties of a selected polypeptide may be quantified by methods well known in the art. One method involves measuring the rates of formation and dissociation of the antigen-binding site / antigen complex, where these rates depend on the concentrations of the complex partners, the affinity of the interaction, and geometric parameters that affect this rate equally in two directions. Therefore, the "association rate constant" (K on ) and "dissociation rate constant" (K off Both the K and K can be determined by calculating the concentration and the actual association and dissociation rates (see Nature 361:186-87 (1993)). off / K on The ratio can be used to eliminate parameters unrelated to affinity, such as the equilibrium dissociation constant K D and is an affinity number (see generally Davies et al. (1990) Annual Rev Biochem 59:439-473). The equilibrium binding constant with OX40 (K D ) is ≦1 μM, an antibody of the disclosure is considered to specifically bind to OX40.

[0096] In the present invention, the fucose "content" of an antibody refers to the molar ratio of glycoforms containing fucose to all glycoforms of the antibody. In some embodiments, the fucose content of the antibody is about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% or more. In some embodiments, the fucose content of the antibody is about 96%. In some embodiments, the fucose content of the antibody does not exceed about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0.5%. In some embodiments, the fucose content of the antibody is about 0.

[0097] As used herein, the term "treatment" refers to prophylactic and / or therapeutic measures aimed at preventing, alleviating, and / or eliminating the progression of adverse physiological alterations or disorders (e.g., cancer). Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, reduction in the extent of disease, stabilization of the disease state (i.e., not worsening), delay or alleviation of disease progression, improvement or amelioration of the disease state, etc. "Treatment" also refers to prolonged survival (compared to desired survival in the absence of treatment). Those in need of treatment include those already suffering from a condition or disorder, as well as those prone to the condition or disorder, or those in need of prevention of the condition or disorder.

[0098] "Patient" generally refers to any subject in need of diagnosis, prognosis, or treatment, particularly a mammalian subject. Mammalian subjects include humans, dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows, etc., particularly humans. In the present invention, for example, a "patient in need of treatment" includes a patient, e.g., a mammalian patient, who would benefit from the administration of an antibody or composition disclosed herein for use in detection, diagnostic processes, prevention and / or treatment.

[0099] Unless otherwise specified, the term "OX40" refers to any naturally occurring OX40 from any vertebrate (including mammals, e.g., primates (e.g., humans, rhesus monkeys), and rodents (e.g., mice and rats)). The term includes "full-length," unprocessed OX40 and any form of OX40 processed in cells.

[0100] "OX40 activation" refers to activation of the OX40 receptor. Generally, OX40 activation results in signal transduction.

[0101] "Activated T cells" refers to the induction, induction, or stimulation of effector or memory T cells to have renewed, sustained, or amplified biological function. Examples of enhanced T cell function include increased secretion of gamma interferon (e.g., IFNg) or interleukin (e.g., IL-2) from CD8+ effector T cells, increased secretion of gamma interferon (e.g., IFNg) or interleukin (e.g., IL-2) from CD4+ memory and / or effector T cells, increased proliferation of CD4+ effector and / or memory T cells, increased proliferation of CD8+ effector T cells, and enhanced antigen responsiveness (e.g., elimination) compared to before the intervention. Relevant measurement methods are known to those skilled in the art.

[0102] The term "cytokine" refers to a group of proteins released by one cell group and acting on another cell as an intercellular medium. Examples of such cytokines include lymphokines, monokines, interleukins (IL) (e.g., IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12, IL-15), tumor necrosis factors (e.g., TNF-α or TNF-β), and other polypeptide factors, including LIF, kit ligand (KL), and gamma interferon. For example, as used herein, the term cytokine includes proteins derived from nature or recombinant cell culture and biologically active equivalents of native-sequence cytokines. Bioactive equivalents also include small molecule entities produced by artificial synthesis, and pharmaceutically acceptable derivatives and salts thereof.

[0103] For example, as used herein, the term "label" or "labeled" refers to the incorporation of a detectable label, for example, by incorporating a radioactively labeled amino acid or a polypeptide attached to a biotin moiety that is detected by labelable avidin (e.g., streptavidin containing a fluorescent label or having enzymatic activity detected by optical or calorimetric methods). In some cases, the marker or label may be therapeutic. A variety of methods for labeling polypeptides and glycoproteins are known and available in the art. Examples of markers for polypeptides include radioisotopes or radionuclides (e.g., 3 H, 14 C. 15 N, 35 S, 90 Y, 99 Tc, 111 In, 125 I, 131 Examples of suitable labels include, but are not limited to, fluorescent markers (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic markers (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase), chemiluminescent labels, biotinyl groups, and predetermined polypeptide epitopes recognized by secondary reporter genes (e.g., leucine zipper pair sequences, secondary antibody binding sites, metal binding domains, epitope tags). In some embodiments, labels are attached via spacer arms of various lengths to reduce potential steric hindrance.

[0104] (Anti-OX40 antibody) The antibodies of the present invention have the ability to bind to OX40 and activate the OX40 intracellular signaling pathway, particularly when Fc receptors or cells expressing Fc receptors are involved, thereby promoting T cell activation and suppressing tumor growth or metastasis. For example, the T cell activation function can be verified using the NFκB reporter gene system described in the Examples herein.

[0105] In some embodiments, the invention provides antibodies or antigen-binding fragments thereof that bind to human OX40 or rhesus OX40. In some embodiments, the anti-OX40 antibodies or antigen-binding fragments thereof of the invention retain strong binding to human OX40 or rhesus OX40 (e.g., comparable to or stronger than known anti-OX40 antibodies such as OX40mAb24 and 11D4).

[0106] In some embodiments, the antibodies or antigen-binding fragments thereof of the invention bind to human OX40 or rhesus OX40. The antibodies or antigen-binding fragments thereof of the invention do not bind or bind relatively poorly to murine OX40, e.g., mouse OX40, compared to their binding to human OX40 or rhesus OX40. In some embodiments, the anti-OX40 antibodies or antigen-binding fragments thereof of the invention bind to human OX40. D is about 20 nM, about 19 nM, about 12 nM, about 6 nM, about 5 nM, about 4 nM, or about 2 nM or less. D is about 1 nM, about 0.8 nM, about 0.6 nM, about 0.4 nM, or about 0.2 nM or less. D is about 0.16 nM. In some embodiments, antibody binding affinity is measured using a bio-optical interference assay (e.g., Fortebio affinity assay).

[0107] In some embodiments, the binding of the antibodies or antigen-binding fragments thereof to human OX40 is measured using flow cytometry. In some embodiments, the binding to human OX40 has an EC50 of about 1.5 nM or less. In some embodiments, the binding to human OX40 has an EC50 of about 1.33 nM or about 1.0 nM or less.

[0108] In some embodiments, the agonist activity of an anti-OX40 antibody is assessed by measuring OX40 signal transduction. This is typically detected using Jurkat cells transfected with OX40 and an NFκB reporter gene. The present invention provides anti-OX40 antibodies or antigen-binding fragments thereof that enhance NFκB-mediated transcriptional activity levels compared to an IgG control antibody. In some embodiments, an anti-OX40 antibody or antigen-binding fragment thereof can increase NFκB-mediated transcriptional activity levels by about 9-fold or more compared to the corresponding control IgG when Raji cells are used. In some embodiments, an anti-OX40 antibody or fragment thereof of the present invention can increase NFκB-mediated transcriptional activity levels by about 5-fold or more compared to the corresponding control IgG.

[0109] In some embodiments, the Fc of an anti-OX40 antibody undergoes RY (E345R and S440Y) and R (E345R) mutations, and then its activity is detected using Jurkat cells transfected with OX40 and an NFκB reporter gene. The activity of the antibody after undergoing the RY mutation is 12-fold higher than that of the antibody without the mutation, while the activity of the antibody after undergoing the R mutation is 10-fold higher than that of the antibody without the mutation.

[0110] In some embodiments, the agonist activity of an anti-OX40 antibody is assessed by the level of cytokine (IL-2) released after PBMC cell activation. The anti-OX40 antibodies or fragments thereof of the present invention can increase the level of IL-2 secreted by PBMC cells by about 1-fold, about 2-fold, about 3-fold, or more compared to a corresponding control IgG.

[0111] In some embodiments, the anti-OX40 antibody or antigen-binding fragment thereof has about a 5-fold, about a 10-fold, about a 20-fold, or about a 70-fold improvement in affinity after undergoing affinity maturation.

[0112] In some embodiments, the anti-OX40 antibodies or antigen-binding fragments thereof of the invention comprise a heavy chain variable region (VH), wherein the VH comprises complementarity determining regions VH CDR1, VH CDR2, and VH CDR3, wherein VH CDR1 comprises or consists of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or 100% identity to an amino acid sequence selected from SEQ ID NOs: 1, 4, 10, 16, 104, or 22; and VH CDR2 comprises or consists of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or 100% identity to an amino acid sequence selected from SEQ ID NOs: 1, 4, 10, 16, 104, or 22; and the VH CDR3 comprises or consists of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity or 100% identity to an amino acid sequence selected from SEQ ID NO: 2, 5, 7, 8, 11, 13, 14, 17, 20, 23 or 26, and the VH CDR3 comprises or consists of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity or 100% identity to an amino acid sequence selected from SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24 or 27.

[0113] In some embodiments, an anti-OX40 antibody or antigen-binding fragment thereof of the invention comprises a light chain variable region (VL), wherein the VL comprises complementarity determining regions (CDRs) VL CDR1, VL CDR2, and VL CDR3, wherein VL CDR1 comprises or consists of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or 100% identity to an amino acid sequence selected from SEQ ID NOs: 28, 31, 37, 40, 43, 46, 49, 52, 55, 58, or 61; and VL CDR2 comprises or consists of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or 100% identity to an amino acid sequence selected from SEQ ID NOs: 28, 31, 37, 40, 43, 46, 49, 52, 55, 58, or 61; and the VL CDR3 comprises or consists of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity or 100% identity to an amino acid sequence selected from SEQ ID NOs: 19, 25, 29, 32, 35, 38, 44, 47, 50, 56, 59 or 62, and the VL CDR3 comprises or consists of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity or 100% identity to an amino acid sequence selected from SEQ ID NOs: 30, 33, 34, 36, 39, 41, 42, 45, 48, 51, 53, 54, 57, 60 or 63. In the antibody or antigen-binding fragment thereof of the present invention, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 may be any one of the exemplary combinations of amino acid sequences corresponding to each CDR in Table 1.

[0114] [Table 1]

[0115] In some embodiments, the anti-OX40 antibody or fragment thereof of the present invention comprises a heavy chain variable region, VH, comprising or consisting of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or 100% identity to an amino acid sequence selected from SEQ ID NOs: 64-72.

[0116] In some embodiments, the anti-OX40 antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region, VL, comprising or consisting of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or 100% identity to an amino acid sequence selected from SEQ ID NOs: 73-84.

[0117] In some embodiments, the heavy chain variable region VH and light chain variable region VL of the antibody or antigen-binding fragment thereof of the present invention are the exemplary combinations shown in Table 3.

[0118] In some embodiments, the antibody or fragment thereof further comprises a heavy chain constant region, a light chain constant region, an Fc region, or a combination thereof.

[0119] In some embodiments, the antibody comprises a heavy chain set forth in SEQ ID NO:86 and a light chain set forth in SEQ ID NO:87.

[0120] The present invention relates to antibodies, antigen-binding fragments, variants, or derivatives. Variants are antibodies or antigen-binding fragments thereof obtained by deleting and / or substituting one or more amino acid residues in the antibody or antigen-binding fragment, or by inserting one or more amino acid residues. Derivatives include modified derivatives, i.e., by covalent attachment of any type of molecule to the antibody, where the covalent attachment does not prevent the antibody from binding to its epitope. Antibodies may be modified by, for example, glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, attachment to cellular ligands or other proteins, and the like, including, but not limited to, the following examples. Any one of numerous chemical modifications may be performed by conventional techniques, including, but not limited to, specific chemical degradation, acetylation, formylation, metabolic synthesis of tunicamycin, and the like. Furthermore, antibodies may contain one or more unnatural amino acids.

[0121] In some embodiments, the antibody can be conjugated to a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a drug, or PEG. The antibody may be conjugated or fused to a therapeutic agent, which may include a detectable label, such as a radiolabel, an immunomodulator, a hormone, an enzyme, an oligonucleotide, a photosensitive therapeutic or diagnostic agent, a drug or toxin cytotoxic agent, an ultrasound-enhancing agent, a non-radioactive label and compositions thereof, and other such reagents known in the art.

[0122] The antibody can be detectably labeled by coupling it to a chemiluminescent compound, and the presence of the chemiluminescent-tagged antigen-binding fragment is determined by detecting the luminescence emitted during the chemical reaction. Examples of particularly useful chemiluminescent labeling compounds include luminol, isoluminol, aromatic acridinium ester, imidazole, acridinium salt, and oxalate ester.

[0123] In some embodiments, the heavy and / or light chains of the anti-OX40 antibodies or fragments thereof of the invention further comprise a signal peptide sequence, such as, for example, MEFGLSWVFLVAILKGVQC (SEQ ID NO:85).

[0124] In some embodiments, the antibodies of the present invention further include amino acid sequence variants of anti-OX40 antibodies and antibodies that bind to the same epitope as any of the above-described antibodies.

[0125] In some embodiments, the anti-OX40 antibodies of the invention further comprise antibody fragments thereof, which in some embodiments are selected from the following antibody fragments: Fab, Fab'-SH, Fv, scFv, or (Fab')2 fragments.

[0126] The anti-OX40 antibodies of the present invention can be prepared by conventional recombinant DNA techniques, for example, by using recombinant DNA techniques known to those skilled in the art to select, construct, and culture antibody-encoding DNA, antibody-producing vectors, and cell lines. These techniques are described in various laboratory manuals and major publications. In this regard, the techniques applicable to the present invention described below are referenced in *Current Protocols in Immunology*, Coligan et al., Eds., Green Publishing Associates and Wiley-Interscience, John Wiley and Sons, New York (1991), the entire contents of which, including any supplements, are incorporated herein by reference.

[0127] In some embodiments, antibody-encoding DNA can be designed and synthesized using conventional methods based on the antibody amino acid sequences described herein, inserted into an expression vector, transfected into host cells, and cultured to produce monoclonal antibodies. In some embodiments, the antibody expression vector contains at least one promoter element, an antibody coding sequence, a transcription termination signal, and a polyA tail. Other elements include an enhancer, a Kozak sequence, and RNA splicing donor and acceptor sites on either side of the insertion sequence. Highly efficient transcription can be achieved using the early and late promoters of SV40, long terminal repeats from retroviruses, such as RSV, HTLV-1, HIV-1, and the early promoter of cytomegalovirus. Other cellular promoters, such as the actin promoter, can also be used. Suitable expression vectors may include pIRES1neo, pRetro-Off, pRetro-On, PLXSN, or Plncx, pcDNA3.1(+ / -), pcDNA / Zeo(+ / -), pcDNA3.1 / Hygro(+ / -), PSVL, PMSG, pRSVcat, pSV2dhfr, pBC12MI, and pCS2, etc. Commonly used mammalian cells include 293 cells, Cos1 cells, Cos7 cells, CV1 cells, mouse L cells, and CHO cells, etc.

[0128] In some embodiments, the inserted gene fragment should contain a screening marker; common screening markers include screening genes such as dihydrofolate reductase, glutamine synthetase, neomycin resistance, hygromycin resistance, etc., to facilitate screening and isolation of successfully transfected cells. The constructed plasmid is transfected into host cells and cultured in a selective medium, and successfully transfected cells grow in large quantities and produce the desired target protein.

[0129] In some embodiments, the present invention provides a nucleic acid encoding any of the above anti-OX40 antibodies or fragments thereof. In one embodiment, a vector comprising the nucleic acid is provided. In one embodiment, the vector is an expression vector. Expression vectors include plasmids, retroviruses, YACs, EBV-induced adducts, and the like. In one embodiment, a host cell comprising the vector is provided. In one embodiment, the host cell is eukaryotic. In another embodiment, the host cell is selected from yeast cells, mammalian cells (e.g., CHO cells or 293F cells), or other cells applied in the preparation of antibodies or antigen-binding fragments thereof.

[0130] In some embodiments, the polynucleotide comprises one or more of the nucleotide sequences set forth in SEQ ID NOs:96-101. In some embodiments, the polynucleotide comprises the nucleotide sequence set forth in SEQ ID NOs:96, 97, and 98. In some embodiments, the polynucleotide comprises the nucleotide sequence set forth in SEQ ID NOs:99, 100, and 101. In some embodiments, the polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO:102. In some embodiments, the polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO:103. In some embodiments, the polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO:102 and / or the nucleotide sequence set forth in SEQ ID NO:103. In some embodiments, a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO:96, 97, 98, 99, 100, or 101 can encode and produce a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:10, 26, 27, 61, 62, or 63, respectively. In some embodiments, a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO:102 can be produced to encode a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:72, and in some embodiments, a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO:103 can be produced to encode a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:84. In some embodiments, a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO:105 can be produced to encode a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:90, and in some embodiments, a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO:106 can be produced to encode a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:91, where each nucleotide sequence is set forth in Table 2 below.

[0131] [Table 2]

[0132] The pharmaceutical compositions of the present invention may comprise the antibodies or antigen-binding fragments thereof of the present invention. These pharmaceutical compositions may be included in reagent kits, such as diagnostic reagent kits. The present invention provides methods for alleviating cancer or other neoplastic or infectious conditions by administering one or more antibodies or fragments described herein to a patient in need thereof. The administered dose of the antibody should be sufficient to alleviate cancer or other neoplastic or infectious conditions in the patient. In some embodiments, the patient is human. In some embodiments, the antibody is chimeric, humanized, or fully human. In some embodiments, the antibody or fragment thereof can activate T cells and promote their proliferation or secretion of inflammatory factors. In some embodiments, the antibody or fragment thereof is an IgG isotype, the IgG isotype being selected from the group consisting of an IgG1 isotype, an IgG2 isotype, an IgG3 isotype, and / or an IgG4 isotype. In some embodiments, the antibody or antigen-binding fragment thereof is an IgG isotype selected from IgG4P and IgG4PE. In some embodiments, the antibody or antigen-binding fragment thereof is an IgG isotype selected from those containing RY(E345R and S440Y) and R(E345R).

[0133] In some embodiments, the anti-OX40 antibody and other therapeutic agent are formulated as a single therapeutic composition, and the anti-OX40 antibody and other therapeutic agent are administered simultaneously. Alternatively, the anti-OX40 antibody and other therapeutic agent are formulated independently of each other, e.g., as separate therapeutic compositions, and the anti-OX40 antibody and other therapeutic agent are administered simultaneously, or at different times during the therapeutic regimen. For example, the anti-OX40 antibody is administered before the other therapeutic agent, or after the other therapeutic agent, or the anti-OX40 antibody and other therapeutic agent are administered in an alternating regimen. As used herein, the anti-OX40 antibody and other therapeutic agent are administered in a single dose or multiple doses.

[0134] Those skilled in the art will appreciate that the antibodies of the present invention have a variety of uses, for example, they can be used as therapeutic agents, as reagents or diagnostic tools in diagnostic reagent kits, or as reagents in competitive experiments to generate therapeutic agents. The present invention provides antibodies and sequences thereof as set forth in Table 3. These antibodies are collectively referred to herein as anti-OX40 antibodies.

[0135] Some properties of the antibodies described herein include specific binding to human OX40 and rhesus OX40, the ability to activate the intracellular signaling pathway of OX40, the ability to promote T cell activation, and the ability to exhibit potent tumor suppressor activity against cancer.

[0136] The equilibrium dissociation constant (K D ) is about 20 nM, about 19 nM, about 12 nM, about 6 nM, about 5 nM, about 4 nM, or about 2 nM or less, as measured using bio-optical interference assays and BIACORE. D is about 1 nM or 0.16 nM or less.

[0137] The equilibrium binding constant (K D ) was measured using flow cytometry. In some embodiments, binding to human OX40 has an EC50 of about 1.5 nM or less. In some embodiments, binding to human OX40 has an EC50 of about 1.33 nM or 1.0 nM or less. The measured K D is less than that of a known control antibody.

[0138] The OX40 activation activity of the anti-OX40 antibodies of the present invention was determined using an NFκB reporter gene system, and the EC50 was approximately 0.14 μg / ml in the presence of protein A, but approximately 0.0602 μg / ml and 0.0722 μg / ml in the presence of Raji cells.

[0139] Exemplary antibodies of the invention include Antibody-F10, Antibody-F15-1L, Antibody-A2, Antibody-X35-6L, Antibody-A6-1k, Antibody-M5-5k, Antibody-M5-7k, Antibody-F23-4k, Antibody-F23-7k, Antibody-F23-32k, Antibody-FE-16H, and Antibody M. Exemplary antibodies of the invention include antibodies containing a variable heavy chain whose sequence is selected from SEQ ID NOs:64-72 and a variable light chain (VL) whose sequence is selected from SEQ ID NOs:73-84. In particular, exemplary antibodies include those provided in Table 3.

[0140] [Table 3-1]

[0141] [Table 3-2]

[0142] The present invention further includes antibodies that bind to the same epitope as the anti-OX40 antibodies described herein. For example, antibodies of the present invention specifically bind to an epitope of one or more amino acid residues on human OX40 (see, e.g., P434489 on Uniprot).

[0143] One of skill in the art will recognize that one can determine, without undue experimentation, whether an antibody binds to the same epitope as an antibody described herein (e.g., one of the antibodies shown in Table 3, or an antibody having a variable heavy chain selected from SEQ ID NOs:64-72 and a variable light chain sequence selected from SEQ ID NOs:73-84) simply by determining whether the test antibody inhibits the binding of a known antibody to OX40. When the test antibody competes with an antibody of the present disclosure, the two antibodies are likely to bind to the same or similar epitope, as indicated by decreased binding of the antibodies described herein.

[0144] An alternative method for determining whether an antibody has the specificity of the antibodies described herein is to preincubate the antibodies described herein with a soluble OX40 protein that is typically reactive with the antibody, and then add the antibody to be tested to determine whether the ability of the antibody to be tested to bind OX40 is inhibited. If the antibody to be tested is inhibited, it has the same epitope specificity as the antibodies of the present disclosure, or is functionally identical.

[0145] In some embodiments, antibodies of the present invention can be prepared using, for example, the methods described in the Examples provided below. In some embodiments, antibodies can also be prepared and produced using trioma technology, human B cell hybridoma technology (see Kozbor et al., 1983, Immunol Today 4:72), and EBV hybridoma technology (see Cole et al., 1985, In: Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).

[0146] Antibodies can be purified by known techniques, such as affinity chromatography or immunoaffinity chromatography using protein A or protein G. For example, D. Wilkinson (The Scientist, The Scientist, Inc., Philadelphia, Pa., Vol. 14, No. 8 (2000), pp. 25-28) has reviewed the purification of immunoglobulins. The monoclonal anti-OX40 antibodies of the present invention have the ability to modulate, enhance, activate, activate, or otherwise activate OX40 intracellular signaling. In some embodiments, anti-OX40 antibodies (e.g., fully humanized or humanized antibodies) can be produced by, for example, yeast surface display methods, as described in WO2009036379 and WO2010105256. In this method, yeast combinatorial libraries containing random light and heavy chain pairs are screened using native or recombinant OX40 or fragments thereof.

[0147] (Fc modification) The associated effector functions of the antibodies described herein can be modified to improve the antibody's effectiveness, for example, in treating diseases and disorders associated with OX40 signaling. For example, because tumor-infiltrating regulatory T cells (Tregs) are ubiquitously expressed, introducing one or more mutations into the Fc region of an antibody can improve ADCC function and thereby more effectively kill Tregs. Furthermore, because sufficient activation of OX40 intracellular signaling requires the aggregation and oligomerization of multiple OX40 receptors, introducing one or more mutations into the Fc region of an antibody can improve the antibody's ability to aggregate or bind to Fc receptors, thereby promoting antibody aggregation and thereby enabling more effective activation of OX40 intracellular signaling.

[0148] In some embodiments, the antibodies described herein are of the IgG isotype. In some embodiments, the constant region of the antibody is of the human IgG1 isotype and has the amino acid sequence of SEQ ID NO:90 and SEQ ID NO:91. In some embodiments, specific amino acids in the human IgG1 constant region are modified to alter the glycosylation of the antibody, for example, defucosylation of N297. In some embodiments, the antibodies or antigen-binding fragments thereof contain low, few, or no fucose modifications, resulting in significantly improved ADCC efficacy. In some examples, the antibodies or fragments thereof have fucose modifications on up to one (or up to two or three) amino acid residues. In some examples, the antibodies or fragments thereof contain less than 0.01%, 0.1%, 1%, 2%, 3%, 4%, or 5% of protein molecules modified with fucose. In some embodiments, antibodies with reduced or eliminated fucose modifications have stronger ADCC and are suitable for some therapeutic applications. In some embodiments, the antibody or antigen-binding fragment thereof is expressed in modified CHO cells. In some embodiments, the modified CHO cells are CHO cells in which one or more of the following genes have been reduced or knocked out: Slc35c1 gene, fut8 gene, GDP-mannose 4,6-dehydratase (GMD) gene, GDP-4-keto-6-deoxymannose-3,5-epimerase-4-reductase (GMER) gene, and GDP-fucose transporter (GFT) gene. In some embodiments, the modified CHO cells are CHO cells in which the fut8 gene has been knocked out.

[0149] In some embodiments, modifications are made to specific amino acids on the antibody constant region to alter Fc receptor interactions, for example, S267E / L328F mutations.

[0150] In some embodiments, the constant region of the antibody is a human IgG2 isotype and has the amino acid sequence of SEQ ID NOs:92 and 93, wherein the amino acid sequence of SEQ ID NO:92 is as follows: ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKDTLMISRTPEVTCVVDVSHEDPEVQFNWYVDGVEV HNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK; wherein the amino acid sequence of SEQ ID NO:93 is as follows: RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.

[0151] In some embodiments, the constant region of the antibody is a human IgG4 isotype and has the amino acid sequence of SEQ ID NOs:94 and 95, wherein the amino acid sequence of SEQ ID NO:94 is as follows: ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEV HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK; wherein the amino acid sequence of SEQ ID NO:95 is as follows: RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.

[0152] In some embodiments, modifications are made to the hinge region in the human IgG4 constant region to prevent or reduce chain exchange, and in other embodiments, modifications are made to amino acid 235 on the human IgG4 constant region to alter Fc receptor interactions.

[0153] (Use for anti-OX40 antibodies or antigen-binding fragments thereof) Diseases or conditions treatable with the anti-OX40 antibodies described herein include hematological cancers and / or solid cancers. Hematological cancers include, for example, leukemia, lymphoma, and myeloma. In some embodiments, leukemias include acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), and myeloproliferative disorders / tumors (MPDS). Lymphomas include Hodgkin's lymphoma, indolent and aggressive non-Hodgkin's lymphoma, Burkitt's lymphoma, and follicular lymphoma (small cell and large cell). Myelomas include multiple myeloma (MM), giant cell myeloma, heavy chain myeloma, and light chain or Bence-Jones myeloma. Solid cancers include, for example, breast cancer, ovarian cancer, lung cancer, pancreatic cancer, prostate cancer, melanoma, colorectal cancer, lung cancer, head and neck cancer, bladder cancer, esophageal cancer, liver cancer, and kidney cancer.

[0154] A therapeutically effective amount of an antibody of the present invention relates to the amount necessary to achieve a therapeutic goal. The amount required for administration depends on the binding affinity of the antibody to its specific antigen, the severity of the disease, disorder, or condition, the route of administration, the rate at which the administered antibody is depleted from the free volume to which it is administered, and other factors. In some embodiments, a therapeutically effective amount of an antibody or antibody fragment of the present invention ranges from about 0.01 mg / kg to about 100 mg / kg. In some embodiments, a therapeutically effective amount of an antibody or antibody fragment of the present invention ranges from about 0.1 mg / kg to about 30 mg / kg. The dosing frequency may be, for example, once every two weeks or once every three weeks.

[0155] In some other embodiments, antibodies to OX40 can be used in methods related to OX40 localization and / or quantification known in the art (e.g., to measure levels of OX40 and / or both OX40 and OX40L in appropriate physiological samples, used in diagnostic methods, used in amyloid imaging, etc.). In some embodiments, the anti-OX40 antibody is administered to a patient who has been diagnosed with one or more clinical symptoms associated with the disease (including, but not limited to, cancer or other neoplastic conditions). After diagnosis, the anti-OX40 antibody is administered to reduce or reverse the effects of one or more clinical symptoms associated with the disease.

[0156] OX40 overexpression is observed in some tumor specimens, and patients with OX40-overexpressing cells may respond to treatment with the anti-OX40 antibodies of the present invention. Therefore, the antibodies of the present invention can also be used for diagnosis and prognosis. In some embodiments, a sample containing cells may be obtained from a patient, who may have cancer or be diagnosed. The cells may be from tumor tissue or a tumor mass, a blood sample, a urine sample, or any sample from a patient. After selective pre-treatment of the sample, the sample can be incubated with an antibody of the invention under conditions that allow interaction of the antibody with OX40 protein that may be present in the sample, and the anti-OX40 antibody can be used to detect the presence of OX40 protein in the sample.

[0157] The antibodies of the invention can also be used to detect OX40 in patient samples and therefore can be used diagnostically. For example, anti-OX40 antibodies of the invention can be used in in vitro tests (e.g., ELISA) to detect OX40 levels in patient samples.

[0158] In one embodiment, the anti-OX40 antibody of the present invention is immobilized on a solid support (e.g., the well of a microtiter plate). The immobilized antibody serves as a capture antibody to capture any OX40 present in the test sample. Before contacting the immobilized antibody with a patient sample, the solid support is washed and treated with a blocking reagent (e.g., milk protein or albumin) to avoid nonspecific adsorption of the analyte. The well is then treated with a test sample that may contain the antigen or a solution containing a standard amount of the antigen. Such samples may be, for example, serum samples from subjects, and may have circulating antigen levels that are believed to be diagnostic of a certain pathology. After washing the test sample or standard, the solid support is treated with a detectably labeled secondary antibody. The labeled secondary antibody is used as a detection antibody. The concentration of OX40 in the test sample is determined by measuring the level of detectable label and comparing it with a standard curve constructed with standard samples.

[0159] Based on results obtained from in vitro diagnostic tests using the anti-OX40 antibodies of the present invention, a subject's disease (e.g., clinical symptoms associated with ischemia, autoimmune, or inflammatory diseases) can be classified based on the expression levels of OX40 and / or OX40L. For a particular disease, blood samples are collected from subjects diagnosed at multiple stages in the progression of the disease and / or at multiple points in the treatment of the disease. A group of samples that provided statistically significant results for each stage of progression or therapy is used to determine the antigen concentration range considered characteristic of each stage.

[0160] In some embodiments, when using the anti-OX40 antibodies or antigen-binding fragments thereof described herein, the antibodies or fragments thereof are present in the form of a pharmaceutical composition. Here, the pharmaceutical composition can consist of the anti-OX40 antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with drug administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences. Such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, glucose solution, and / or 5% human serum albumin.

[0161] The formulation of a drug composition should be compatible with its desired route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions for parenteral, intradermal, or subcutaneous administration may contain the following components: a sterile injectable diluent, e.g., water, saline, fixed oils, polyethylene glycols, glycerin, propylene glycol, or other synthetic solvents; an antibacterial agent, e.g., benzyl alcohol or methyl parahydroxybenzoate; an antioxidant, e.g., ascorbic acid or sodium bisulfite; a chelating agent, e.g., ethylenediaminetetraacetic acid (EDTA); a buffer, e.g., acetate, citrate, or phosphate; and an agent for adjusting the tonicity, e.g., sodium chloride or dextrorotatory glucose. The pH can be adjusted with acids or bases, e.g., hydrochloric acid or sodium hydroxide. Parenteral formulations can be packaged in ampoules, disposable syringes, or multi-dose bottles made of glass or plastic.

[0162] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, or phosphate-buffered saline (PBS). In some embodiments, the composition must be sterile and easy to inject. It must be stable under the conditions of manufacture and storage and must be capable of preventing the contaminating action of microorganisms, such as bacteria and fungi. The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. In some embodiments, pharmaceutically acceptable carriers may also be realized by including antibacterial and / or antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In some embodiments, pharmaceutically acceptable carriers may also include isotonic agents, such as sugars, polyols (e.g., erythritol, sorbitol), and sodium chloride.

[0163] As needed, a sterile injectable solution can be prepared by mixing the antibody in the desired amount in an appropriate solvent with one or more combinations of the above ingredients (as needed), followed by filtered sterilization. The above sterile solution can also be freeze-dried to obtain a powder that can be used to prepare a sterile injectable solution at the time of administration.

[0164] In some embodiments, the antibodies of the invention are capable of activating an immune response and are thereby used to treat infection.

[0165] Infection is the invasion of living tissue by pathogenic agents, their proliferation, and the host's tissue's response to these organisms and the toxins they produce. Infection can be caused by infectious agents such as viruses, viroids, prions, bacteria, nematodes such as parasitic roundworms and pinworms, arthropods such as ticks, mites, fleas, and lice, fungi such as crickets, and other macroparasites such as tapeworms and other helminths. In some embodiments, the infectious agent is a bacterium, such as a gram-negative bacterium. In some embodiments, the infectious agent is a virus, such as a DNA virus, an RNA virus, or a retrovirus. Viruses include, but are not limited to, adenovirus, coxsackievirus, Epstein-Barr virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, herpes simplex virus type 1, herpes simplex virus type 2, giant cell virus, human herpes virus type 8, HIV, influenza virus, measles virus, parotitis virus, human papillomavirus, parainfluenza virus, poliovirus, rabies virus, respiratory syncytial virus, rubella virus, and varicella-zoster virus.

[0166] The antibodies of the present invention can be used to treat infectious diseases caused by microorganisms, or can be used to eliminate microorganisms by targeting and killing the microorganisms and immune cells. In some embodiments, the microorganism is a virus, including RNA and DNA viruses, Gram-positive bacteria, Gram-negative bacteria, protozoa, or fungi. [Example]

[0167] Example 1: Production and purification of OX40 antigen and control antibody 1.1 Preparation of Humanized OX40 Antigen The amino acid sequence of human OX40 (P43489) was found in the protein database Uniprot, where the amino acid sequence of the extracellular domain of human OX40 was found to be residues 1 to 216. The amino acid sequence of human IgG1-Fc (P01857) was found to be residues 104 to 330. Subsequently, the nucleotide sequences corresponding to OX40 and Fc were obtained by artificial synthesis (General Motors Corporation), enzymatic cleavage, and insertion into pCDNA3.0 carrier (purchased from Invitrogen). The recombinant plasmids pCDNA-OX40-his and pCDNA-OX40-Fc were obtained. Furthermore, HEK293 cells were transiently transfected with the above plasmids using PEI. After 7 days of culture, the supernatant was collected and finally purified to obtain hOX40-FC and hOX40-his protein samples, which were used in the various examples below.

[0168] 1.2 Preparation of positive control antibodies 11D4 and OX40mAb24 The heavy and light chain sequences of 11D4 were derived from US Patent US8236930. The heavy and light chain sequences of OX40mAb24 were derived from US Patent US2016 / 0137740. The corresponding nucleotide sequences were obtained by artificial synthesis and then enzymatically cleaved to combine the heavy and light chain nucleotides into the pCHO1.0 plasmid (purchased from Invitrogen), respectively, to obtain recombinant plasmids for expressing the complete antibodies. According to the manufacturer's instructions, the recombinant plasmids were transformed into CHO-S cells using the Freedom CHO-S Reagent Kit (purchased from Invitrogen). After 11 days of culture, the supernatants were collected and finally purified to obtain 11D4 and OX40mAb24 antibody protein samples, which were used in the various examples below.

[0169] Example 2: Preparation of anti-OX40 antibody The corresponding nucleic acid sequences for the variable regions of antibodies Nos. 1 to 11 shown in Table 3, the heavy chain constant region shown in SEQ ID NO:90, and the light chain constant region shown in SEQ ID NO:91 were inserted into the pCHO1.0 plasmid (purchased from Invitrogen) using molecular cloning techniques to obtain recombinant plasmids for expressing complete antibodies. According to the manufacturer's instructions, the recombinant plasmids were transformed into CHO-S cell lines using the Freedom CHO-S Reagent Kit (purchased from Invitrogen). After culturing for 11 days, the supernatants were collected and finally purified to obtain protein samples of the 11 antibody strains. The sequences were confirmed by sequencing and used in the various examples below.

[0170] wherein the sequence of the heavy chain constant region, SEQ ID NO:90, is as follows: ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK The sequence of the light chain constant region, SEQ ID NO:91, is as follows: RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Example 3: Measurement of binding ability of anti-human OX40 antibody 3.1 Measurement of the affinity of anti-human OX40 antibodies by bio-optical interference ForteBio affinity measurements were performed according to conventional methods (Estep, P. et al., MAbs, 2013, 5(2):270-8). The outline of the process is as follows: the sensor was equilibrated offline for 20 minutes with an analysis buffer, such as PBS, followed by online detection for 60 seconds to establish a signal baseline. The purified antibody obtained as described above was then loaded onto the corresponding sensor (ForteBio). Finally, ForteBio affinity measurements were performed. Biotinylated candidate antibodies were adsorbed on the SA sensor, and binding and dissociation of hOX40-FC were detected, each for approximately 5 minutes. The results are shown in Table 4, where ND indicates not detected. Finally, kinetic analysis was performed using a 1:1 binding model. The results showed that the affinities of some of the antibodies of the present invention were superior to or similar to those of the control antibody.

[0171] [Table 4]

[0172] 3.2 Cell surface antigen binding ability of anti-human OX40 antibodies Jurkat cells overexpressing human OX40 (Jurkat-hOX40 cells) were generated by transfecting a pCMV carrier carrying human OX40 cDNA. Jurkat-hOX40 cells (0.5 × 10 6 Cells were incubated with 100 nM of experimental antibody in PBS containing 0.1% BSA for 40 minutes on ice. Cells were then washed twice and incubated with secondary antibody in PBS containing 0.1% BSA for 25 minutes on ice. Cells were washed twice and analyzed by flow cytometry on an Accuri C6 system (BD Biosciences). The results are shown in Figure 1. Jurkat-hOX40 cells were incubated with various concentrations of antibodies, including antibody-F23-4k and antibody-F23-32k, as well as two control antibodies, 11D4 and OX40mAb24. Antibody concentrations were diluted three-fold from 50 nM for a total of nine concentration points. MFIs were calculated and the data processed using SoftMax Pro. EC50 values ​​were determined to be 1.5 nM, 1.0 nM, 1.5 nM, and 5 nM, respectively.

[0173] PBMC cells (purchased from Raitoku Bio) derived from healthy individuals were activated with anti-CD3 / CD28 magnetic beads (purchased from Invitrogen) for 48 hours, and 0.5 × 10 6 Cells were incubated with 50 nM of experimental antibodies in PBS for 40 minutes. Then, the cells were washed twice and incubated with anti-FC-PE secondary antibody (purchased from ebioscience) in PBS on ice for 30 minutes. The cells were washed twice and analyzed by flow cytometry, and the MFI was calculated. The results are shown in Table 5.

[0174] [Table 5]

[0175] Example 4: Specificity of anti-human OX40 antibody Similar to the method in Example 3.2, 100 nM of the experimental antibodies were incubated with Jurkat cells (Jurkat-TIM3, Jurkat-CTLA4, Jurkat-TIGIT), CHO, and Raji cells overexpressing different antigens, and then analyzed by flow cytometry. The results are shown in Figure 2. The results showed that antibody-F23-32k did not significantly bind to these antigens or cell lines, suggesting good specificity. Using ELISA, 10 ng of mouse OX40-his (mOX40-his), hCD27-FC, and hOX40-his were coated and incubated overnight at 4°C. After washing, the plate was further incubated with antibody-F23-32K and a control antibody. Finally, the plate was labeled and developed with an HRP-conjugated secondary antibody. The OD values ​​obtained are shown in Table 6. As in Example 3.2, the protein A sensor was set up according to the process program for antibody-OX40-his (100 nM). The affinity of antibody-F23-32K with the control antibody and rhesus monkey OX40 (Rh-OX40) was measured using Fortebio. The results are shown in Table 6. These results indicate that antibody-F23-32K did not bind to hCD27 (a protein of the same family as hOX40) or mouse OX40, but did significantly bind to rhesus monkey OX40.

[0176] [Table 6]

[0177] Example 5: Detection of biological activity of anti-OX40 antibodies 5.1 Detection of in vitro activating activity of candidate antibodies using an NFκB reporter gene system Based on the Jurkat-hOX40 from Example 3.2, the pGL6-NFkB-lufiferas-reporter plasmid (purchased from Biyuntian) was electrotransformed into the cells. Finally, a stable monoclonal strain was obtained by antibiotic pressure screening and named Jurkat-hOX40-NFkB. The cells were resuscitated and subcultured three times, after which 20x10 4 Plate cells / well according to the cell count, add 60 μl of medium per well, add 1 μg / ml of the corresponding experimental antibody and 2.5 μg / ml of anti-FC antibody (goat anti-human, purchased from Invitrogen), incubate for 5 hours, then add 50 μl of fluorescent reaction mixture (ONE-Glo TMLuciferase Assay System (purchased from Promega) was added to each well, and the results are shown in Figure 3. As can be seen from the data, the activation signals of the experimental antibodies at a concentration of 1 μg / ml were all stronger than those of the control antibody.

[0178] Following the method described above, Jurkat-hOX40-NFκB-2 cells with a larger window value were reconstituted and used to verify the activating activity of antibodies. Some studies have suggested that antibodies against activating target receptors require Fc-R involvement for potent activating activity. Similarly to the method described above, Jurkat-hOX40-NFκB-2 cells were resuscitated and passaged three times, after which 4x10 4 Plates were plated according to cells / well, and 60 μl of medium per well was added to the plate. The corresponding experimental antibody and 40,000 Raji cells (which naturally have certain Fc-receptors (i.e., Fc-R) on their surface) were added per well. After 4.5 hours of incubation, 50 μl of fluorescent reaction mixture was added per well. The results are shown in Table 7. The data suggest that the presence of Raji cells can significantly improve the activation activity of candidate antibodies.

[0179] [Table 7]

[0180] Jurkat-hOX40-NFκB-2 cells were resuscitated and passaged three times, followed by 4x10 4 Cells were plated onto plates at 1000 x g / well, with 60 μl of medium per well. Experimental antibodies were incubated with protein A / G at a 1:1 ratio for 2 min at a starting concentration of 1.5 μg / ml, followed by gradient dilutions. The results are shown in Figure 4. The EC50 values ​​for antibodies F23-32k and 11D4 were 0.1405 μg / ml and 0.2261 μg / ml, respectively.

[0181] 5.2 Detection of the effect of antibodies on IL-2 secretion by activated PBMCs The agonist activity of the anti-OX40 antibodies of the present invention was evaluated by measuring the inflammatory cytokines released from T cells after T cell activation. After obtaining PBMCs, they were plated at 200,000 cells / well and 200 μL of medium was added to a 96-well plate. 80 μg / ml SEB was added to activate the PBMCs. Two days later, the PBMCs were collected. After washing, the plates were plated at 200,000 cells / well and 200 μL of medium. 1 μg / ml of candidate or control antibody and 2 μg / ml of anti-FC antibody (goat anti-human, purchased from Invitrogen) were added. After three days, IL-2 secretion levels in the medium were detected using an ELISA reagent kit. The results are shown in Figure 5. Similar to the procedure described above, 1 μg / ml of candidate or control antibody was first coated onto the plate overnight at 4°C. After washing the plate three times, the activated PBMCs were plated at 200,000 cells / well and 200 μL of medium. After 3 days, the IL-2 secretion level in the medium was measured using an ELISA reagent kit (purchased from Xinbosheng), and the results are shown in Figure 5. The data suggested that the antibody of the present invention, F23-32k, was equivalent to a positive control.

[0182] Example 6: Enhancement of Fc mutations on anti-OX40 antibody biological activity Two IgG1-Fc mutant sequences were obtained by artificial synthesis, with RY (E345R and S440Y) and R (E345R), respectively, and named IgG1-FC-RY (SEQ ID NO: 88) and IgG1-FC-R (SEQ ID NO: 89). The sequences are shown in Table 8 (underlined positions indicate mutation positions). Antibody-F23-32k was subjected to RY or R mutation, and the resulting antibodies were named 32k-RY and 32k-R, respectively. HPLC analysis confirmed that the antibodies existed primarily as free monomers. Jurkat-hOX40-NFκB-2 and Jurkat-hOX40-NFκB cells were resuscitated and used in the following experiments. Similar to the procedure in Example 5.1, the cells were passaged three times, and then 4 x 10 4Plates were plated with 200,000 cells / well, and the appropriate antibody (1 μg / ml), antibody mutant (1 μg / ml), Raji cells (10,000 cells per well), or protein A (1 μg / ml, purchased from Sangon Biotech) was added. The sample regimen and combinations added to the 96-well plate are shown in Figure 6, along with the results. Antibodies containing the RY or R mutation significantly activated OX40 signals even in the absence of protein A, and were approximately 10-fold more potent than wild-type antibodies.

[0183] [Table 8]

[0184] Example 7: Verification of the ability of anti-OX40 antibodies to suppress tumors using a model in which humanized mice were inoculated with MC38 tumors The antitumor effect of the anti-OX40 antibody of the present invention was examined in an OX40 humanized mouse model (purchased from Baiaosaitu). MC38 tumor cells were cultured at 5 × 10 5 The tumor was subcutaneously inoculated into the right side of a humanized female mouse with B-hOX40 at a concentration of 0.1 ml / 100 cells / 0.1 mL. 3 When tumors reached tumor size, they were randomly assigned to groups with six mice per group. Antibodies were administered intraperitoneally at a frequency of Q3D (once every three days) at 3 mg / kg for a total of six doses. PBS served as a negative control.

[0185] Tumors and body weights were measured twice weekly throughout the study period, and mice were euthanized when tumors reached the endpoint or when they lost 20% of their body weight. For each group, the mean tumor volume was estimated using digital calipers and calculated as tumor volume (mm) using the following formula: 3 ) was calculated, and the (width) of each group was 2 × Length / 2 is about 50mm 3The results are shown in Figure 7. In Figure 7, TGI% is the tumor volume inhibition rate, calculated by the formula: TGI% = (1 - (mean RTV-treated group) / (mean RTV-control group)) × 100%, where mean RTV-treated group is the mean RTV of the treated group, mean RTV-control group is the mean RTV of the control group, RTVn = Vnt / Vn0, where Vnt is the tumor volume on day t of mouse number n, Vn0 is the tumor volume on day 0 of mouse number n, and RTVn is the relative tumor volume on day t of mouse number n. The heavy chain of antibody 4K-RY was obtained from FC mutations (E345R and S440Y) of antibody-F23-4k.

[0186] The purpose of this study was to further understand the effect of the experimental antibody on tumor-infiltrating T cells (TIL). After the above experiment was completed, appropriate mice were selected, with four mice per group. Tumor-infiltrating lymphatic T cells and blood lymphatic T cells were obtained using conventional dissection methods. The cells were then fluorescently labeled with different markers, and finally, fluorescent detection was performed using a flow cell sorter. The results showed that the experimental antibody of the present invention increased the proportion of intratumoral CD4+ and CD8+ T cells. However, it did not affect the proportion of blood CD4+ and CD8+ T cells.

[0187] Example 8 1) Affinity maturation and affinity measurement of candidate antibodies Table 9 lists several mutations in the CDRs of antibody-F23-32K, where the underlined amino acids indicate the mutation sites. Table 10 lists the CDRs of eight complete antibodies with these amino acid mutations; the remaining sequences are the same as antibody-F23-32K. Their affinities were measured using BIACORE. A specific probe was first used to bind the antibody, and then the binding and dissociation of 20 nM OX40-His was detected. The results are shown in Table 11, where the affinity of antibody M was approximately 70-fold improved, reaching 0.16 nM, approximately 21-fold higher than that of OX40mAb24 and approximately 9-fold higher than that of antibody 11D4. Similarly, Jurkat cells overexpressing OX40 were incubated with different concentrations of WEST+VGTD and ST+VGTD antibodies. The resulting EC50 values ​​were 1.2 nM and 1.3 nM, respectively. The results are shown in Figure 8. The sequence of the anti-OX40 antibody (antibody M) is as shown in Table 12. The expression cells used for the above antibodies (including antibody M) were CHO-S cells, and antibody M-KF was prepared using a CHO cell line in which the fut8 gene was knocked out and whose amino acid sequence is the same as that of antibody M-KF (the fucose content of antibody M-KF was approximately 0%).

[0188] [Table 9]

[0189] [Table 10]

[0190] [Table 11]

[0191] [Table 12]

[0192] 2) Detection of antibody antigen-binding specificity The binding ability of antibody M-KF to human and cynomolgus monkey OX40 was measured using an ELISA method. Human or cynomolgus monkey OX40 was coated overnight at 4°C at a concentration of 2 μg / ml, and then various concentrations of antibody M-KF were incubated and detected. The starting concentration of antibody M-KF was 1 μg / ml or 2 μg / ml, and diluted in a 2-fold gradient.

[0193] As can be seen from the results, antibody M-KF was able to bind to human and cynomolgus monkey OX40, with binding EC50 values ​​of approximately 0.0340 ng / ml and 0.0352 ng / ml, respectively.

[0194] Example 9: ADCC effector and in vitro activation activity of antibodies The fucose content of antibody M was approximately 96%. The fucose content of antibody M-KF was approximately 0%. FC-RIIIA and NF-AT reporter genes were transfected into Jurkat cells to obtain Jurkat-ADCC cells. Jurkat-hOX40 cells and Jurkat-ADCC cells were mixed at a 1:1 ratio, and antibody M and antibody M-KF were added at corresponding concentration gradients. The results are shown in Figure 9. The in vitro activation activity of candidate antibodies was detected using the NFκB reporter gene system as described above (Example 5). Jurkat-hOX40-NFκB-2 cells were resuscitated and passaged three times, after which 4x10 4 The cells were plated at 1000 cells / well, and 40,000 Raji cells were added to each well in 60 μl of medium and the corresponding experimental antibody. The results are shown in Figure 10. The EC50 values ​​of antibody M and antibody M-KF were slightly better than that of 11D4, but the peak activation value of both antibodies was approximately 2.5 times that of the latter.

[0195] Example 10: In vitro pharmacodynamic testing of antibodies As described above, the antitumor effect of the anti-OX40 antibody of the present invention was examined in an OX40 humanized mouse model (purchased from Baiaosaitu). MC38 tumor cells were cultured at 5 × 10 5 The tumors were inoculated subcutaneously into the right side of humanized female mice with B-hOX40 at a concentration of 0.1 ml / 1000 cells / 0.1 mL. The tumor growth was 119 mm. 3When tumors reached tumor size, they were randomly assigned to groups with six mice per group. A series of endotoxin-free antibodies, Antibody M and Antibody M-KF, were expressed and purified and administered intraperitoneally at three doses: 1 mg / kg, 0.2 mg / kg, and 0.04 mg / kg, according to the Q3D frequency. A total of six doses were administered.

[0196] Tumors and body weights were measured twice weekly throughout the study period, and mice were euthanized when tumors reached the endpoint or when they lost 20% of their body weight. For each group, the mean tumor volume was estimated using digital calipers and calculated as tumor volume (mm) using the following formula: 3 ) was calculated, and the (width) of each group was 2 × Length / 2 is approximately 50 mm 3 The results are shown in Figure 11, and the results on day 21 are shown in Figure 12. The high-dose groups of antibody M and antibody M-KF were able to significantly inhibit tumor growth (P<0.05), and the effect was significantly better than that of the high-dose group of 11D4. The medium-dose group of antibody M-KF was also able to significantly inhibit tumor growth (P<0.05).

[0197] Example 11: ADCC effector of antibodies (PBMC method) Jurkat-hOX40 cells were used as target cells, and PBMCs derived from healthy donors were used as effector cells. PBMCs and Jurkat-OX40 cells were mixed at a ratio of 25:1, and antibody M-KF or antibody M (starting at 1 μg / ml and diluted 4-fold) was added. The mixture was incubated at 37°C for 4 hours. The corresponding signals were then measured using the CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega) reagent kit. This system detected the ADCC-mediated cytotoxicity of the antibodies.

[0198] The results are shown in FIG. 13. Antibody M-KF had a clear ADCC effect, with an EC50 of approximately 1.891 ng / ml, which was two times stronger than that of antibody M.

[0199] Example 12: Detection of the effect of antibodies on IL-2 secretion from activated PBMCs ELISA was used to detect the release of IL-2 cytokines from human peripheral blood mononuclear cells (PBMCs) stimulated with the antibody M-KF. PBMCs were stimulated with SEB (Staphylococcal enterotoxin B) for 24 hours, and then various concentrations of antibody M-KF or the reference antibody 11D4 were added and incubated for three consecutive days. Finally, IL-2 secreted from PBMCs was detected using a Human IL-2 ELISA development kit (HRP) reagent kit (Mabtech, product number 3445-1H-20).

[0200] The results are shown in FIG. 14. At concentrations of 0.32 μg / ml or more, antibody M-KF stimulated PBMC to secrete about four times as much IL-2 as the negative control IgG1.

[0201] Example 13: Detection of the effect of antibodies on PBMC cytokine release under non-activating conditions We used ELISA to detect the release of IL-2, INF-γ, IL-6, and TNF-α cytokines from human PBMCs without exogenous stimulation, thereby detecting the activating effectors of the antibody M-KF and examining its safety. The ultimate goal of the antibody M-KF's mechanism of action is to stimulate the immune system and enhance immune function by activating T cells. From a safety perspective, such antibodies may lead to excessive activation of the immune system, thereby inducing a cytokine storm. IL-2, INF-γ, IL-6, and TNF-α are all factors commonly produced in large quantities during a cytokine storm, and these factors were selected for detection.

[0202] Unactivated human PBMCs were incubated with different concentrations of M-KF or CD28 antibodies, starting at 200 μg / ml and diluted three-fold. Finally, the cytokines secreted by PBMCs were detected using the corresponding cytokine detection kits from Mabtech.

[0203] As shown in Figure 15, compared to the positive control CD28 antibody, antibody M-KF was unable to induce the production of IL-2, INF-γ, IL-6, or TNF-α from PBMCs without exogenous stimulation at concentrations of 200 μg / mL or lower, and antibody M-KF is therefore expected to have a certain degree of safety.

[0204] All publications and patent documents cited herein are incorporated by reference in their entirety as if each individual publication or document was specifically and individually indicated to be incorporated by reference herein. Citation of such publications and patent documents is not an admission that any of the material therein is pertinent prior art, nor is it an admission as to the content or date thereof. While the invention has been described herein in terms of a specification, those skilled in the art will recognize that the invention can be practiced in various embodiments, and that the foregoing specification and examples are intended to illustrate, but not limit, the scope of the invention as claimed.

Claims

1. An antibody or antigen-binding fragment thereof, wherein the antibody or fragment thereof specifically binds to OX40, and the antibody or fragment thereof comprises: (a) comprising a VH CDR1 as set forth in SEQ ID NO:4, a VH CDR2 as set forth in SEQ ID NO:5, a VH CDR3 as set forth in SEQ ID NO:6, a VL CDR1 as set forth in SEQ ID NO:31, a VL CDR2 as set forth in SEQ ID NO:32, and a VL CDR3 as set forth in SEQ ID NO:33; or (b) comprising a VH CDR1 as set forth in SEQ ID NO: 10, a VH CDR2 as set forth in SEQ ID NO: 11, a VH CDR3 as set forth in SEQ ID NO: 12, a VL CDR1 as set forth in SEQ ID NO: 37, a VL CDR2 as set forth in SEQ ID NO: 38, and a VL CDR3 as set forth in SEQ ID NO: 39; or (c) comprising a VH CDR1 set forth in SEQ ID NO: 10, a VH CDR2 set forth in SEQ ID NO: 11, a VH CDR3 set forth in SEQ ID NO: 12, a VL CDR1 set forth in SEQ ID NO: 43 or 61, a VL CDR2 set forth in SEQ ID NO: 44, and a VL CDR3 set forth in SEQ ID NO: 39; or (d) comprising a VH CDR1 as set forth in SEQ ID NO: 16, a VH CDR2 as set forth in SEQ ID NO: 17, a VH CDR3 as set forth in SEQ ID NO: 18, a VL CDR1 as set forth in SEQ ID NO: 52, a VL CDR2 as set forth in SEQ ID NO: 29, and a VL CDR3 as set forth in SEQ ID NO: 54; or (e) comprising a VH CDR1 set forth in SEQ ID NO: 10, a VH CDR2 set forth in SEQ ID NO: 26, a VH CDR3 set forth in SEQ ID NO: 27, a VL CDR1 set forth in SEQ ID NO: 43, a VL CDR2 set forth in SEQ ID NO: 25, and a VL CDR3 set forth in SEQ ID NO: 34; or (f) comprising a VH CDR1 set forth in SEQ ID NO: 10, a VH CDR2 set forth in SEQ ID NO: 11, a VH CDR3 set forth in SEQ ID NO: 27, a VL CDR1 set forth in SEQ ID NO: 43, a VL CDR2 set forth in SEQ ID NO: 25, and a VL CDR3 set forth in SEQ ID NO: 34; or (g) comprising a VH CDR1 as set forth in SEQ ID NO: 10, a VH CDR2 as set forth in SEQ ID NO: 11, a VH CDR3 as set forth in SEQ ID NO: 12, a VL CDR1 as set forth in SEQ ID NO: 43, a VL CDR2 as set forth in SEQ ID NO: 25, and a VL CDR3 as set forth in SEQ ID NO: 34; or (h) comprising a VH CDR1 as set forth in SEQ ID NO: 10, a VH CDR2 as set forth in SEQ ID NO: 26, a VH CDR3 as set forth in SEQ ID NO: 27, a VL CDR1 as set forth in SEQ ID NO: 43, a VL CDR2 as set forth in SEQ ID NO: 25, and a VL CDR3 as set forth in SEQ ID NO: 39; or (i) An antibody or antigen-binding fragment thereof, comprising a VH CDR1 shown in SEQ ID NO: 10, a VH CDR2 shown in SEQ ID NO: 26, a VH CDR3 shown in SEQ ID NO: 27, a VL CDR1 shown in SEQ ID NO: 43, a VL CDR2 shown in SEQ ID NO: 44, and a VL CDR3 shown in SEQ ID NO:

34.

2. The antibody or antigen-binding fragment thereof comprises a heavy chain variable region, wherein the heavy chain variable region comprises any one of the amino acid sequences set forth in SEQ ID NO: 65, 67, 69 or 72, or a peptide having at least 90% sequence identity to any one of the amino acid sequences set forth in SEQ ID NO: 65, 67, 69 or 72; and / or 2. The antibody or antigen-binding fragment thereof of claim 1, further comprising a light chain variable region, wherein the light chain variable region comprises any one of the amino acid sequences set forth in SEQ ID NOs: 74, 76, 78, 81, or 84, or a peptide having at least 90% sequence identity to any one of the amino acid sequences set forth in SEQ ID NOs: 74, 76, 78, 81, or 84.

3. An antibody or antigen-binding fragment thereof, comprising a heavy chain variable region set forth in SEQ ID NO: 72 and a light chain variable region set forth in SEQ ID NO:

84.

4. The antibody or fragment thereof according to any one of claims 1 to 3, wherein the antibody or fragment thereof comprises a heavy chain constant region and / or a light chain constant region, wherein the heavy chain constant region is the heavy chain constant region shown in SEQ ID NO: 88, 89 or 90, and / or the light chain constant region is the light chain constant region shown in SEQ ID NO:

91.

5. An antibody, characterized in that said antibody comprises a heavy chain set forth in SEQ ID NO:86 and a light chain set forth in SEQ ID NO:

87.

6. The antibody or fragment thereof according to any one of claims 1 to 5, wherein the affinity value KD of the antibody or fragment thereof for OX40 is ≦5 nM.

7. The antibody or fragment thereof according to any one of claims 1 to 6, wherein the fucose content of the antibody does not exceed 10%.

8. The antibody or fragment thereof according to any one of claims 1 to 6, wherein the antibody is expressed by a CHO cell in which the fut8 gene has been knocked out.

9. The antibody or fragment thereof according to claim 8, wherein the fucose content of the antibody is 0%.

10. A polynucleotide, characterized in that the polynucleotide encodes the antibody or fragment thereof according to any one of claims 1 to 9.

11. A cell, characterized in that the cell comprises one or more polynucleotides encoding the antibody or fragment thereof according to any one of claims 1 to 9.

12. A composition comprising the antibody or fragment thereof according to any one of claims 1 to 9, the polynucleotide according to claim 10, or the cell according to claim 11, and a pharmaceutically acceptable carrier.

13. A composition for treating cancer or infection, comprising an antibody or fragment thereof described in any one of claims 1 to 9.

14. 14. The composition of claim 13, wherein the cancer is selected from non-Hodgkin's lymphoma, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, multiple myeloma, breast cancer, ovarian cancer, head and neck cancer, bladder cancer, melanoma, colorectal cancer, pancreatic cancer, lung cancer, leiomyoma, leiomyosarcoma, glioma, glioblastoma, prostate cancer, esophageal cancer, liver cancer, and kidney cancer.

15. 14. The composition of claim 13, wherein the composition further comprises a second cancer therapeutic agent.

Images